id stringlengths 11 11 | problem_number int64 1 20k | title stringlengths 51 333 | statement stringlengths 182 873 | clean_statement stringlengths 151 658 | plain_language_statement stringlengths 125 688 | background stringlengths 609 1.29k | question_type stringclasses 20
values | category_id stringclasses 20
values | category_num int64 1 20 | primary_category stringclasses 20
values | set_id stringclasses 40
values | is_gold_seed bool 2
classes | condition_name stringlengths 8 146 | population_description stringlengths 8 353 | question_framework_type stringclasses 9
values | intervention_or_focus stringlengths 4 223 | comparator_or_reference stringlengths 6 218 | time_horizon stringclasses 17
values | translational_stage stringclasses 9
values | evidence_state stringclasses 6
values | consensus_state stringclasses 3
values | difficulty_level_id int64 1 5 | research_difficulty stringclasses 5
values | status stringclasses 3
values | publication_class stringclasses 4
values | proposed_by stringlengths 87 182 | proposed_year int64 2.02k 2.03k | source_url stringlengths 29 60 | source_citation stringlengths 48 303 | active_trial stringlengths 73 168 | literature_papers_count int64 3 3 | total_sources_per_problem int64 5 5 | published bool 1
class |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
UMED-000001 | 1 | Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2- Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy — Open Classification Question | Among adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, can a reproducible subphenotype taxonomy based on Consensus-Based risk stratification algorithm for HR+/HER2- early breast cancer to guide adjuvant CDK4/6i therapy resolve clinical heterogeneity an... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does Consensus-Based risk stratification algorithm compare with conventional clinicopathologic staging and consensus taxonomy regarding overall survival and progression-free or disease-free surviv... | In patients affected by early-stage hormone-receptor-positive HER2-negative breast cancer, what is the clearest medical evidence on whether Consensus-Based risk stratification algorithm works better than conventional clinicopathologic staging and consensus taxonomy over 60 months? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of development ... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | prognostic | Consensus-Based Risk Stratification Algorithm | Conventional clinicopathologic staging and consensus taxonomy | 60 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Mallavarapu KM et al., Jin X et al., Qureshi Z et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.2147/bctt.s620643 | Mallavarapu KM et al., Breast cancer (Dove Medical Press) (2026); DOI: 10.2147/bctt.s620643 | NCT03078751 (PHASE2, COMPLETED): Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Ca (SRC-MED-NCT-0003) | 3 | 5 | true |
UMED-000002 | 2 | Large B-cell lymphoma (LBCL) — Open Diagnosis Question | For adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy in ambulatory specialty, laboratory or pathology care, can tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias reduce diagnostic delay and misclassification compared with standar... | In adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy, how does tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias compare with standard pre-infusion clinical risk scores regarding overall survival and progression-free or disease-fr... | Can tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with standard pre-infus... | In oncology and hematology, managing diffuse large b-cell lymphoma relapsing after first-line chemoimmunotherapy (primary refractory or early relapse <=12 months) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Diffuse large B-cell lymphoma relapsing after first-line chemoimmunotherapy | Adults with primary refractory or early relapsed DLBCL receiving CD19-directed CAR-T cell therapy | PIRD | Tumor-intrinsic and microenvironmental drivers of CD19 CAR-T resistance and late cytopenias | Standard pre-infusion clinical risk scores (IPI and LDH) | 24 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Thieblemont C et al., Liu Z et al., Fu X et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,025 | https://doi.org/10.1002/hem3.70207 | Thieblemont C et al., HemaSphere (2025); DOI: 10.1002/hem3.70207 | NCT01410630 (OBSERVATIONAL, COMPLETED): FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (SRC-MED-NCT-0019) | 3 | 5 | true |
UMED-000003 | 3 | Adherence of Oncologists and Cardiologists to Venous Thromboembolic Disease Prevention and Treatment Guidelines in Cancer Patients — Open Implementation Question | Among ambulatory specialty practices managing adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does structured clinical pathway integration of adherence of oncologists and cardiologists to venous thromboembolic disease preventio... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months compare with continued full-dose DOAC or weight-adjusted daltep... | Among individuals with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (including thrombocytopenia 25-50 x10^9/L, hepatic or renal dysfunction), does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months offer meaningf... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | implementation | Reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months | Continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin | 24 months | implementation | multiple_small_studies | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Turk UO et al., Kania J et al., Zhanghuang C et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.3390/jcm15124504 | Turk UO et al., Journal of clinical medicine (2026); DOI: 10.3390/jcm15124504 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000004 | 4 | Clinical Management of Acute Graft-Versus-Host Disease — Open Comparative Effectiveness Question | Across diverse clinical cohorts of children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare against extracorporeal ph... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare with extracorporeal photopheresis or calcineurin-inhibito... | What are the real-world benefits and risks of ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD versus extracorporeal photopheresis or calcineurin-inhibitor continuation over 24 months for patients managing steroid-refractory acute and chronic graft-versus-host disease after ... | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD | Extracorporeal photopheresis or calcineurin-inhibitor continuation | 24 months | comparative_effectiveness | systematic_review_low_certainty | active_scientific_dispute | 2 | moderate | contested | DISPUTED-OPEN | DeFilipp Z et al., Chalchal H et al., Arcuri LJ et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1016/j.jtct.2026.04.053 | DeFilipp Z et al., Transplantation and cellular therapy (2026); DOI: 10.1016/j.jtct.2026.04.053 | NCT04744116 (EARLY_PHASE1, RECRUITING): Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatmen (SRC-MED-NCT-0038) | 3 | 5 | true |
UMED-000005 | 5 | Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH) — Open Diagnosis Question | In patients with paroxysmal nocturnal hemoglobinuria (PNH) presenting for clinical evaluation, what is the diagnostic accuracy and clinical utility of diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compared with conventional clinicopathologic, imaging, or laboratory reference standard for improvi... | In patients with paroxysmal nocturnal hemoglobinuria (PNH), how does diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding annualized bleeding or crisis rate, hemoglobin stabilization, and event-free surviva... | For people with paroxysmal nocturnal hemoglobinuria (PNH), how does diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria (PNH) compare with conventional clinicopathologic, imaging, or laboratory reference standard for improving annualized bleeding or crisis rate, hemoglobin stabilization, and event-free surv... | In oncology and hematology, managing paroxysmal nocturnal hemoglobinuria (PNH) (clinically characterized human cohort) requires balancing annualized bleeding or crisis rate, hemoglobin stabilization, and event-free survival and thromboembolic events, hemolysis or bleeding breakthroughs, and immunogenicity. Studies of e... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Patients with paroxysmal nocturnal hemoglobinuria (PNH) | PIRD | Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH) | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | BLOCKED-OPEN | Fattizzo B et al., Liu H et al., Obara N et al. & National Academies of Sciences, Engineering, and Medicine (NASEM) Health and Medicine Division | 2,026 | https://doi.org/10.1111/ejh.70294 | Fattizzo B et al., European journal of haematology (2026); DOI: 10.1111/ejh.70294 | NCT06839456 (PHASE1/PHASE2, RECRUITING): Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/C (SRC-MED-NCT-0052) | 3 | 5 | true |
UMED-000006 | 6 | Assessment of Large Language Models in Colorectal Cancer Multidisciplinary Tumor Board Decision-Making — Open Implementation Question | In routine clinical practice for patients with colorectal cancer multidisciplinary tumor board Decision-Making, does a multifaceted implementation bundle for assessment of large language models outperform usual guideline dissemination without multifaceted implementation strategy in adoption, sustainment, and overall su... | In patients with colorectal cancer multidisciplinary tumor board Decision-Making, how does large language models compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 60 months? | In patients affected by colorectal cancer multidisciplinary tumor board Decision-Making, what is the clearest medical evidence on whether large language models works better than usual guideline dissemination without multifaceted implementation strategy over 60 months? | In oncology and hematology, managing colorectal cancer multidisciplinary tumor board Decision-Making (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of assessment of larg... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Colorectal Cancer Multidisciplinary Tumor Board Decision-Making | Patients with colorectal cancer multidisciplinary tumor board Decision-Making | implementation | Large Language Models | Usual guideline dissemination without multifaceted implementation strategy | 60 months | implementation | multiple_small_studies | broad_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Farzaliyeva A et al., Ito K et al., Shan H et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3390/curroncol33060309 | Farzaliyeva A et al., Current oncology (Toronto, Ont.) (2026); DOI: 10.3390/curroncol33060309 | NCT06832917 (PHASE3, NOT_YET_RECRUITING): Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant (SRC-MED-NCT-0013) | 3 | 5 | true |
UMED-000007 | 7 | The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management in Early Breast Cancer — Open Rehabilitation Question | For adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy in ambulatory specialty rehabilitation pathways, does individualized therapy with the 11th korean breast cancer society consensus conference on axillary management produce durable gains in overall sur... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does the 11th korean breast cancer society consensus conference on axillary management compare with usual physical and functional care without structured rehabilitation pathway regarding overall s... | Can the 11th korean breast cancer society consensus conference on axillary management safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with usual physical and functiona... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of the 11th kor... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | The 11th Korean Breast Cancer Society Consensus Conference on Axillary Management | Usual physical and functional care without structured rehabilitation pathway | 60 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Bae SJ et al., Mallavarapu KM et al., Hannoun-Levi JM et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.4048/jbc.2026.0144 | Bae SJ et al., Journal of breast cancer (2026); DOI: 10.4048/jbc.2026.0144 | NCT06781281 (OBSERVATIONAL, RECRUITING): NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. (SRC-MED-NCT-0001) | 3 | 5 | true |
UMED-000008 | 8 | Tackling similarities and differences in global practice guidelines for gastric cancer — Open Implementation Question | Among ambulatory specialty practices managing patients with global practice guidelines for gastric cancer, how does structured clinical pathway integration of tackling similarities and differences compare with usual guideline dissemination without multifaceted implementation strategy for achieving equitable overall sur... | In patients with global practice guidelines for gastric cancer, how does tackling similarities compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 48 months? | Among individuals with global practice guidelines for gastric cancer (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does tackling similarities offer meaningful long-term benefits over usual guideline dissemination without multifaceted implementation strategy across 48 months? | In oncology and hematology, managing global practice guidelines for gastric cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of tackling similarities and difference... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Global practice guidelines for gastric cancer | Patients with global practice guidelines for gastric cancer | implementation | Tackling similarities | Usual guideline dissemination without multifaceted implementation strategy | 48 months | implementation | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Yen CC et al., Sun Q et al., Lu Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1007/s10120-026-01753-8 | Yen CC et al., Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026); DOI: 10.1007/s10120-026-01753-8 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000009 | 9 | Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome — Open Prevention Question | Across community and clinical cohorts of adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, does sustained preventive intervention with delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endo... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does delphi panel consensus on recommendations compare with routine risk-factor modification or standard surveillance without targeted prophylaxis regarding recurrent venous th... | What are the real-world benefits and risks of delphi panel consensus on recommendations versus routine risk-factor modification or standard surveillance without targeted prophylaxis over 24 months for patients managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Delphi panel consensus on recommendations | Routine risk-factor modification or standard surveillance without targeted prophylaxis | 24 months | population_health | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Isand K et al., Li HY et al., Hashem M et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1093/ejendo/lvaf017 | Isand K et al., European journal of endocrinology (2025); DOI: 10.1093/ejendo/lvaf017 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000010 | 10 | Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma — Open Supportive Palliative Question | For patients with head and neck squamous cell carcinoma experiencing symptom burden, does integrated supportive or palliative care via combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors improve EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden and overall survival... | In patients with head and neck squamous cell carcinoma, how does combination of Anti-EGFR monoclonal antibodies compare with usual symptom-directed care without integrated supportive pathway regarding overall survival and progression-free or disease-free survival over 18 months? | For people with head and neck squamous cell carcinoma, how does combination of Anti-EGFR monoclonal antibodies compare with usual symptom-directed care without integrated supportive pathway for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immune... | In oncology and hematology, managing head and neck squamous cell carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of expert consensus on the combination of Anti-... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and neck squamous cell carcinoma | Patients with head and neck squamous cell carcinoma | PICOTS | Combination of Anti-EGFR monoclonal antibodies | Usual symptom-directed care without integrated supportive pathway | 18 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Xue L et al., Srinivasmurthy R et al., Inoue T et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,025 | https://doi.org/10.1016/j.ctrv.2025.103048 | Xue L et al., Cancer treatment reviews (2025); DOI: 10.1016/j.ctrv.2025.103048 | NCT07110662 (PHASE1/PHASE2, NOT_YET_RECRUITING): New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibod (SRC-MED-NCT-0049) | 3 | 5 | true |
UMED-000011 | 11 | Accuracy of large language models in interpreting urological clinical guidelines — Open Diagnosis Question | Among patients with interpreting urological clinical guidelines, does integrating accuracy of large language models into the diagnostic pathway outperform conventional clinicopathologic, imaging, or laboratory reference standard in sensitivity, specificity, and downstream overall survival and progression-free or diseas... | In patients with interpreting urological clinical guidelines, how does large language models compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by interpreting urological clinical guidelines, what is the clearest medical evidence on whether large language models works better than conventional clinicopathologic, imaging, or laboratory reference standard over 24 months? | In oncology and hematology, managing interpreting urological clinical guidelines (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of accuracy of large language models in i... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Interpreting urological clinical guidelines | Patients with interpreting urological clinical guidelines | PIRD | Large language models | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Borque-Fernando Á et al., Yu H et al., Thieblemont C et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1177/17562872261436905 | Borque-Fernando Á et al., Therapeutic advances in urology (2026); DOI: 10.1177/17562872261436905 | NCT01410630 (OBSERVATIONAL, COMPLETED): FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (SRC-MED-NCT-0019) | 3 | 5 | true |
UMED-000012 | 12 | Immune Checkpoint Inhibitor-Associated Acute Kidney Injury — Open Health Services Question | Among patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology (especially high-risk clinical subgroups, underrepresented age and comorbidity strata), what is the cost-effectiveness, capacity impact, and clinical effect on overall survival and progression-free or dise... | In patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury compare with conventional specialty or hospital-centered care delive... | Can guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 m... | In oncology and hematology, managing immune checkpoint Inhibitor-Associated acute kidney injury (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of immune checkpoint Inhib... | health_services | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune Checkpoint Inhibitor-Associated Acute Kidney Injury | Patients evaluated for immune checkpoint Inhibitor-Associated acute kidney injury in oncology and hematology | health_systems | Guideline-directed clinical management and biomarker stratification in immune checkpoint Inhibitor-Associated acute kidney injury | Conventional specialty or hospital-centered care delivery model | 18 months | health_system | observational_only | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Gupta S et al., Zhang N et al., Qiao T et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1681/asn.0000001232 | Gupta S et al., Journal of the American Society of Nephrology : JASN (2026); DOI: 10.1681/asn.0000001232 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000013 | 13 | Local management of second ipsilateral breast cancer events after primary breast-conserving therapy — Open Public Health Question | For public health programs serving adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, does community-wide deployment of local management of second ipsilateral breast cancer events after primary breast-conserving therapy achieve sustainable improvements i... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does local management of second ipsilateral breast cancer events compare with status-quo population health policy without targeted equity intervention regarding overall survival and progression-fr... | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does local management of second ipsilateral breast cancer events offer meaningful long-term benefits over status-quo population health policy without targeted equit... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of local manage... | public_health | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | health_systems | Local management of second ipsilateral breast cancer events | Status-quo population health policy without targeted equity intervention | 60 months | population_health | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Hannoun-Levi JM et al., Bae SJ et al., Yao S et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1016/s1470-2045(26)00177-4 | Hannoun-Levi JM et al., The Lancet. Oncology (2026); DOI: 10.1016/s1470-2045(26)00177-4 | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000014 | 14 | Management of venous thromboembolism in stroke — Open Implementation Question | In scaling evidence-based care for adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, does audit-feedback and decision support for venous thromboembolism in stroke close care gaps across thrombocytopenia 25-50 x10^9/L, hepatic or rena... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months compare with continued full-dose DOAC or weight-adjusted daltep... | What are the real-world benefits and risks of reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months versus continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin over 24 months for patients managing cancer-associated venous thromboembolism in active gastr... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | implementation | Reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months | Continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin | 24 months | implementation | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Li HY et al., Isand K et al., Prandoni P et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1016/j.thromres.2025.109515 | Li HY et al., Thrombosis research (2025); DOI: 10.1016/j.thromres.2025.109515 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000015 | 15 | Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer — Open Diagnosis Question | In patients with head and neck cancer presenting for clinical evaluation, what is the diagnostic accuracy and clinical utility of defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions compared with conventional clinicopathologic, imaging, or laboratory reference standard for im... | In patients with head and neck cancer, how does defining physician acceptance of radiosensitivity testing compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-free survival over 24 months? | For people with head and neck cancer, how does defining physician acceptance of radiosensitivity testing compare with conventional clinicopathologic, imaging, or laboratory reference standard for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immu... | In oncology and hematology, managing head and neck cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of defining physician acceptance of radiosensitivity testing for... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and neck cancer | Patients with head and neck cancer | PIRD | Defining physician acceptance of radiosensitivity testing | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Thariat J et al., Petit C et al., Tomizawa K et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ctro.2026.101208 | Thariat J et al., Clinical and translational radiation oncology (2026); DOI: 10.1016/j.ctro.2026.101208 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000016 | 16 | Defining the Role of SABR in Head and Neck Cancer — Open Measurement Question | Among patients with head and neck cancer, is defining the role of SABR a validated surrogate or core outcome measure capable of reliably predicting overall survival and progression-free or disease-free survival over 24 months compared with legacy clinician-rated or unharmonized outcome assessment instrument? | In patients with head and neck cancer, how does defining the role of SABR compare with legacy clinician-rated or unharmonized outcome assessment instrument regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by head and neck cancer, what is the clearest medical evidence on whether defining the role of SABR works better than legacy clinician-rated or unharmonized outcome assessment instrument over 24 months? | In oncology and hematology, managing head and neck cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of defining the role of SABR in head and neck cancer (Petit C et... | measurement | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Head and Neck Cancer | Patients with head and neck cancer | PIRD | Defining the Role of SABR | Legacy clinician-rated or unharmonized outcome assessment instrument | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Petit C et al., Thariat J et al., Lee JH et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ijrobp.2026.05.019 | Petit C et al., International journal of radiation oncology, biology, physics (2026); DOI: 10.1016/j.ijrobp.2026.05.019 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000017 | 17 | Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma — Open Prognosis Question | Across independent cohorts of patients with osteosarcoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), how reliably does Real-World achievement of Guideline-Concordant treatment and survival predict long-term overall survival and progression-free or disease-free survival and Gra... | In patients with osteosarcoma, how does Real-World achievement of Guideline-Concordant treatment compare with standard clinical risk score without Real-World achievement of Guideline-Concordant treatment stratification regarding overall survival and progression-free or disease-free survival over 24 months? | Can Real-World achievement of Guideline-Concordant treatment safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with standard clinical risk score without Real-World achie... | In oncology and hematology, managing osteosarcoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Real-World achievement of Guideline-Concordant treatment and survival... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Osteosarcoma | Patients with osteosarcoma | prognostic | Real-World Achievement of Guideline-Concordant Treatment | Standard clinical risk score without Real-World achievement of Guideline-Concordant treatment stratification | 24 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Fujiwara T et al., Otto SD et al., Suprasert P et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1111/cas.70525 | Fujiwara T et al., Cancer science (2026); DOI: 10.1111/cas.70525 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000018 | 18 | Risk-adapted neck dissection in salivary gland carcinoma — Open Implementation Question | Among ambulatory specialty, laboratory or pathology practices managing patients with salivary gland carcinoma, how does structured clinical pathway integration of risk-adapted neck dissection compare with usual guideline dissemination without multifaceted implementation strategy for achieving equitable overall survival... | In patients with salivary gland carcinoma, how does risk-adapted neck dissection compare with usual guideline dissemination without multifaceted implementation strategy regarding overall survival and progression-free or disease-free survival over 24 months? | Among individuals with salivary gland carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does risk-adapted neck dissection offer meaningful long-term benefits over usual guideline dissemination without multifaceted implementation strategy across 24 months? | In oncology and hematology, managing salivary gland carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of risk-adapted neck dissection in salivary gland carcinoma ... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Salivary gland carcinoma | Patients with salivary gland carcinoma | implementation | Risk-adapted neck dissection | Usual guideline dissemination without multifaceted implementation strategy | 24 months | implementation | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Johnson F et al., Song Y et al., Zhang H et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3389/fonc.2026.1916521 | Johnson F et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1916521 | NCT01490723 (PHASE2, COMPLETED): Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) (SRC-MED-NCT-0020) | 3 | 5 | true |
UMED-000019 | 19 | SEOM-GEICO clinical guidelines on endometrial cancer (2025) — Open Implementation Question | In scaling evidence-based care for patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology, does audit-feedback and decision support for guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025... | In patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) compare with usual guideline dissemination without multifaceted im... | What are the real-world benefits and risks of guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) versus usual guideline dissemination without multifaceted implementation strategy over 24 months for patients managing SEOM-GEICO clinical guid... | In oncology and hematology, managing SEOM-GEICO clinical guidelines on endometrial cancer (2025) (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of SEOM-GEICO clinical gu... | implementation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | SEOM-GEICO clinical guidelines on endometrial cancer (2025) | Patients evaluated for SEOM-GEICO clinical guidelines on endometrial cancer (2025) in oncology and hematology | implementation | Guideline-directed clinical management and biomarker stratification in SEOM-GEICO clinical guidelines on endometrial cancer (2025) | Usual guideline dissemination without multifaceted implementation strategy | 24 months | implementation | multiple_small_studies | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Ramírez SP et al., Junling L et al., Wang ZH et al. & World Health Organization (WHO) Global Research Agenda | 2,025 | https://doi.org/10.1007/s12094-025-04046-1 | Ramírez SP et al., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2025); DOI: 10.1007/s12094-025-04046-1 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000020 | 20 | International Dermoscopy Society consensus recommendations for the management of lentigo maligna — Open Etiology Question | In patients with lentigo maligna, what is the causal contribution of international dermoscopy society consensus recommendations for the management of lentigo maligna—and its interaction with host susceptibility—to disease development and overall survival and progression-free or disease-free survival over 36 months comp... | In patients with lentigo maligna, how does international dermoscopy society consensus recommendations compare with unexposed or baseline reference risk cohort in lentigo maligna regarding overall survival and progression-free or disease-free survival over 36 months? | For people with lentigo maligna, how does international dermoscopy society consensus recommendations compare with unexposed or baseline reference risk cohort in lentigo maligna for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immune-mediated adv... | In oncology and hematology, managing lentigo maligna (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of international dermoscopy society consensus recommendations for the... | etiology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Lentigo maligna | Patients with lentigo maligna | PECO | International Dermoscopy Society consensus recommendations | Unexposed or baseline reference risk cohort in lentigo maligna | 36 months | fundamental_human_mechanism | observational_only | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Forsea AM et al., Ru Y et al., Ito K et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1111/jdv.70406 | Forsea AM et al., Journal of the European Academy of Dermatology and Venereology : JEADV (2026); DOI: 10.1111/jdv.70406 | NCT02789254 (PHASE1/PHASE2, COMPLETED): FLYSYN in MRD Positive AML (SRC-MED-NCT-0010) | 3 | 5 | true |
UMED-000021 | 21 | Efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic non-small cell lung cancer — Open Safety Question | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade (especially patients with treated brain metastases, autoimmune comorbidity), what patient-level risk factors and monitoring thresholds predict severe Grade >=3 treatment-related and immune-mediated ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does efficacy compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 48 months? | In patients affected by metastatic non-small cell lung cancer without targetable driver mutations, what is the clearest medical evidence on whether efficacy works better than alternative active comparator or standard dose-monitoring regimen over 48 months? | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safe... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Efficacy | Alternative active comparator or standard dose-monitoring regimen | 48 months | post_authorization | one_pivotal_study | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Han H et al., Zhao Y et al., Mahato S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1820515 | Han H et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1820515 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000022 | 22 | Nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy in pMMR/MSS locally advanced rectal cancer — Open Treatment Strategy Question | Among adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, when can therapy be safely de-escalated, switched, or intensified using nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy compared with mandatory radical total mes... | In adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, how does organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy compare with mandatory radical total mesorectal excision regardless of clinical response regarding... | Can organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with man... | In oncology and hematology, managing locally advanced mismatch-repair-proficient rectal adenocarcinoma (clinical stage T3-T4 or node-positive) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of nonlinear durati... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Locally advanced mismatch-repair-proficient rectal adenocarcinoma | Adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy | PICOTS | Organ-preserving watch-and-wait surveillance after clinical complete response to total neoadjuvant therapy | Mandatory radical total mesorectal excision regardless of clinical response | 60 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Hu S et al., Eltahir AA et al., Sileika E et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3389/fonc.2026.1855615 | Hu S et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1855615 | NCT07580339 (PHASE2, NOT_YET_RECRUITING): Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Adva (SRC-MED-NCT-0015) | 3 | 5 | true |
UMED-000023 | 23 | Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer — Open Prognosis Question | For adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, can baseline and serial assessment of PIK3CA mutations for response to CDK4/6 inhibitors accurately stratify individual risk of overall survival and progression-free or disease-free survival over 60 ... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does PIK3CA mutations compare with standard clinical risk score without PIK3CA mutations stratification regarding overall survival and progression-free or disease-free survival over 60 months? | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does PIK3CA mutations offer meaningful long-term benefits over standard clinical risk score without PIK3CA mutations stratification across 60 months? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of predictive value of PIK3C... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | prognostic | PIK3CA Mutations | Standard clinical risk score without PIK3CA mutations stratification | 60 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Qureshi Z et al., Zhang M et al., Veta Darkovski J et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1097/coc.0000000000001294 | Qureshi Z et al., American journal of clinical oncology (2026); DOI: 10.1097/coc.0000000000001294 | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000024 | 24 | Reduced Versus Full-Dose Direct Oral Anticoagulants for Venous Thromboembolism in Cancer Patients — Open Methodology Question | When validating predictive or causal claims regarding reduced versus Full-Dose direct oral anticoagulants for venous thromboembolism in adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, what external transportability and bias-quantif... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over 24 mo... | What are the real-world benefits and risks of reduced direct oral anticoagulants versus Full-Dose direct oral anticoagulants over 24 months for patients managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Bakht D et al., Akhtar M et al., Joshi DK et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.1002/jha2.70155 | Bakht D et al., EJHaem (2025); DOI: 10.1002/jha2.70155 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000025 | 25 | Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism — Open Methodology Question | In clinical studies of adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation addressing Reduced-Dose versus Full-Dose direct oral anticoagulants, which study design and causal-inference framework best resolves confounding, time-zero bias,... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over ... | For people with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants for improving recurrent venous thromboembolism and clinically relevant bleeding and minimizing ISTH major bl... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced-Dose Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Akhtar M et al., Bakht D et al., Bacha Z et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1007/s10557-025-07759-1 | Akhtar M et al., Cardiovascular drugs and therapy (2026); DOI: 10.1007/s10557-025-07759-1 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000026 | 26 | Immune-related adverse events with cancer clinical benefits — Open Safety Question | In patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology (especially high-risk clinical subgroups, underrepresented age and comorbidity strata), what patient-level risk factors and monitoring thresholds predict severe Grade >=3 treatment-related and immune-mediate... | In patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits compare with alternative active comparator or standard dose-monito... | In patients affected by immune-related adverse events with cancer clinical benefits, what is the clearest medical evidence on whether guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits works better than alternative active comparator or stan... | In oncology and hematology, managing immune-related adverse events with cancer clinical benefits (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of immune-related adverse... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune-related adverse events with cancer clinical benefits | Patients evaluated for immune-related adverse events with cancer clinical benefits in oncology and hematology | PICOTS | Guideline-directed clinical management and biomarker stratification in immune-related adverse events with cancer clinical benefits | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Li Z et al., Chen B et al., Zhu J et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12885-026-16446-9 | Li Z et al., BMC cancer (2026); DOI: 10.1186/s12885-026-16446-9 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000027 | 27 | Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism — Open Methodology Question | In synthesizing heterogeneous evidence on Reduced-Dose vs Full-Dose direct oral anticoagulants for extended anticoagulation therapy in adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, can individual participant data meta-analysis or... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does Reduced-Dose direct oral anticoagulants compare with Full-Dose direct oral anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over ... | Can Reduced-Dose direct oral anticoagulants safely improve recurrent venous thromboembolism and clinically relevant bleeding and quality of life (anticoagulation treatment burden and health-related quality of life) over 24 months compared with Full-Dose direct oral anticoagulants for people with cancer-associated venou... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Reduced-Dose Direct Oral Anticoagulants | Full-Dose Direct Oral Anticoagulants | 24 months | confirmatory_clinical | systematic_review_low_certainty | specialist_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Joshi DK et al., Bakry HE et al., Bitonti TM et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1016/j.jscai.2026.105317 | Joshi DK et al., Journal of the Society for Cardiovascular Angiography & Interventions (2026); DOI: 10.1016/j.jscai.2026.105317 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000028 | 28 | CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients — Open Natural History Question | In unselected prospective follow-up of adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, what factors modify longitudinal progression to overall survival and progression-free or disease-free survival over 60 months under CDK4/6 inhibitors rechallenge po... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does CDK4/6 inhibitors rechallenge post-progression compare with standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer regarding o... | Among individuals with early-stage hormone-receptor-positive HER2-negative breast cancer (including premenopausal women, patients >=70 years with frailty), does CDK4/6 inhibitors rechallenge post-progression offer meaningful long-term benefits over standard longitudinal clinical surveillance cohort in early-stage hormo... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of CDK4/6 inhibitors rechall... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | natural_history | CDK4/6 inhibitors rechallenge post-progression | Standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer | 60 months | early_clinical | observational_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Veta Darkovski J et al., Birsin Z et al., Ye M et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1186/s13058-026-02311-x | Veta Darkovski J et al., Breast cancer research : BCR (2026); DOI: 10.1186/s13058-026-02311-x | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000029 | 29 | Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC — Open Treatment Strategy Question | In patients with advanced or metastatic NSCLC, does dynamic treatment adaptation guided by PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs improve overall survival and progression-free or disease-free survival over 48 months compared with standard fixed-duration or unselected dosing regimen in a... | In patients with advanced or metastatic NSCLC, how does PD-1/PD-L1 inhibitors combined compare with standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC regarding overall survival and progression-free or disease-free survival over 48 months? | What are the real-world benefits and risks of PD-1/PD-L1 inhibitors combined versus standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC over 48 months for patients managing advanced or metastatic NSCLC? | In oncology and hematology, managing advanced or metastatic NSCLC (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced or metastatic NSCLC | Patients with advanced or metastatic NSCLC | PICOTS | PD-1/PD-L1 inhibitors combined | Standard fixed-duration or unselected dosing regimen in advanced or metastatic NSCLC | 48 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Tang Z et al., Kong Y et al., Han H et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1799126 | Tang Z et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1799126 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000030 | 30 | First-line therapies with maintenance regimens for driver gene-negative advanced non-small cell lung cancer (NSCLC) — Open Treatment Strategy Question | For adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade in ambulatory specialty settings, what is the optimal sequencing, dosing threshold, or treatment duration of first-line therapies with maintenance regimens for driver gene-negative advanced non-sma... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does first-line therapies with maintenance regimens compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutation... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does first-line therapies with maintenance regimens compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations for improving overall survival... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of first-line therapies wit... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | First-line therapies with maintenance regimens | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Zhao Y et al., Peruzzo N et al., Wang Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.21037/jtd-2025-aw-2087 | Zhao Y et al., Journal of thoracic disease (2026); DOI: 10.21037/jtd-2025-aw-2087 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000031 | 31 | The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer — Open Natural History Question | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does the long-term clinical course of overall survival and progression-free or disease-free survival evolve over 24 months when stratified by PARP inhibitor-based targeted therapy on BRCA-muta... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does PARP inhibitor-based targeted therapy compare with standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovari... | In patients affected by BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer, what is the clearest medical evidence on whether PARP inhibitor-based targeted therapy works better than standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-profi... | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (FIGO stage III-IV post-platinum) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | natural_history | PARP inhibitor-based targeted therapy | Standard longitudinal clinical surveillance cohort in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer | 24 months | early_clinical | observational_only | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Panjarwanto DA et al., Feng J et al., Salutari V et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1778168 | Panjarwanto DA et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1778168 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000032 | 32 | Treatment outcomes for patients with newly diagnosed or relapsed/refractory TP53-mutated mantle cell lymphoma — Open Screening Question | For risk-stratified adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, does longitudinal surveillance using treatment outcomes reduce late-stage presentation and improve overall survival and progression-free or disease-free survival over 36 months compared... | In adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, how does treatment outcomes compare with symptom-prompted clinical evaluation or current guideline screening schedule regarding overall survival and progression-free or disease-free survival over 36 mon... | Can treatment outcomes safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 36 months compared with symptom-prompted clinical evaluation or current guideline screening schedule for people wit... | In oncology and hematology, managing relapsed or refractory follicular and mantle cell lymphoma (relapsed or refractory stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of treatment outcomes for patients ... | screening | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed or refractory follicular and mantle cell lymphoma | Adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma | PIRD | Treatment outcomes | Symptom-prompted clinical evaluation or current guideline screening schedule | 36 months | population_health | observational_only | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Zhang N et al., Castillo DR et al., Fonseca JM et al. & Cochrane Collaboration Evidence Synthesis Group | 2,025 | https://doi.org/10.1016/j.eclinm.2025.103336 | Zhang N et al., EClinicalMedicine (2025); DOI: 10.1016/j.eclinm.2025.103336 | NCT00293345 (PHASE1, COMPLETED): 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (SRC-MED-NCT-0047) | 3 | 5 | true |
UMED-000033 | 33 | Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer — Open Treatment Strategy Question | What is the optimal clinical algorithm for initiating and sequencing Anti-PD-(l)1 plus chemotherapy relative to standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations to maximize overall survival and progression-free or disease-free survival ove... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does Anti-PD-(l)1 plus chemotherapy compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations regarding over... | Among individuals with metastatic non-small cell lung cancer without targetable driver mutations (including patients with treated brain metastases, autoimmune comorbidity), does Anti-PD-(l)1 plus chemotherapy offer meaningful long-term benefits over standard fixed-duration or unselected dosing regimen in metastatic non... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Anti-PD-(l)1 plus chemot... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Anti-PD-(L)1 plus chemotherapy | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Peruzzo N et al., Qin X et al., Song Q et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1080/1750743x.2026.2689298 | Peruzzo N et al., Immunotherapy (2026); DOI: 10.1080/1750743x.2026.2689298 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000034 | 34 | CAR-T Versus Non-CAR-T Bridging Strategies Before Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia — Open Rehabilitation Question | Across heterogeneous recovery profiles in patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia, which subgroups derive clinically meaningful functional benefit from CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell transplantation over 36 months compared with usual ph... | In patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia, how does CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell compare with usual physical and functional care without structured rehabilitation pathway regarding overall survival and progression-free or disease-fre... | What are the real-world benefits and risks of CAR-T versus Non-CAR-T bridging strategies before allogeneic hematopoietic stem cell versus usual physical and functional care without structured rehabilitation pathway over 36 months for patients managing Relapsed/Refractory B-Cell acute lymphoblastic leukemia? | In oncology and hematology, managing Relapsed/Refractory B-Cell acute lymphoblastic leukemia (relapsed or refractory stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of CAR-T versus Non-CAR-T bridging str... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Patients with Relapsed/Refractory B-Cell acute lymphoblastic leukemia | PICOTS | CAR-T Versus Non-CAR-T Bridging Strategies Before Allogeneic Hematopoietic Stem Cell | Usual physical and functional care without structured rehabilitation pathway | 36 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Halloumi O et al., Dong R et al., Abdelmagid M et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.7759/cureus.115393 | Halloumi O et al., Cureus (2026); DOI: 10.7759/cureus.115393 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000035 | 35 | Circulating Tumor DNA is Associated With Pathologic Response and Survival Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy — Open Prognosis Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, what is the externally validated prognostic discrimination, calibration, and decision utility of circulating tumor DNA is associated with pathologic response and survival outcomes versus standar... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does circulating tumor DNA is associated with pathologic response compare with standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification r... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does circulating tumor DNA is associated with pathologic response compare with standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification for improving overall survival an... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of circulating tumor DNA is... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | prognostic | Circulating Tumor DNA is Associated With Pathologic Response | Standard clinical risk score without circulating tumor DNA is associated with pathologic response stratification | 48 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Song Q et al., Chen Z et al., Kakouri AC et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.arbres.2026.05.021 | Song Q et al., Archivos de bronconeumologia (2026); DOI: 10.1016/j.arbres.2026.05.021 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000036 | 36 | FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia — Open Supportive Palliative Question | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, what is the comparative effectiveness of early, structured FLAG-Based versus standard 7+3 induction therapy versus standard 7+3 induction therapy for relieving refractory symptom... | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, how does FLAG-Based 7+3 induction therapy compare with standard 7+3 induction therapy regarding overall survival and progression-free or disease-free survival over 36 months? | In patients affected by acute myeloid leukemia in first complete remission, what is the clearest medical evidence on whether FLAG-Based 7+3 induction therapy works better than standard 7+3 induction therapy over 36 months? | In oncology and hematology, managing acute myeloid leukemia in first complete remission (first complete remission (CR1)) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of FLAG-Based versus standard 7+3 inducti... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Acute myeloid leukemia in first complete remission | Adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine | PICOTS | FLAG-Based 7+3 Induction Therapy | Standard 7+3 Induction Therapy | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 5 | frontier | open | OPEN-VERIFIED | Abdulgayoom M et al., Chang YS et al., Fathima S et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1159/000552987 | Abdulgayoom M et al., Oncology (2026); DOI: 10.1159/000552987 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000037 | 37 | Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma — Open Safety Question | For patients with metastatic urothelial carcinoma receiving treatment in inpatient ward, ambulatory specialty settings, how does the long-term safety and pharmacovigilance profile of fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition compare with alternative active comp... | In patients with metastatic urothelial carcinoma, how does fibroblast growth factor receptor 3 (FGFR3) alterations compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Can fibroblast growth factor receptor 3 (FGFR3) alterations safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with alternative active comparator or standard dose-monitor... | In oncology and hematology, managing metastatic urothelial carcinoma (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of fibroblast growth factor receptor 3 (FGFR3) alterations and... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic urothelial carcinoma | Patients with metastatic urothelial carcinoma | PICOTS | Fibroblast growth factor receptor 3 (FGFR3) alterations | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Oey O et al., Ma Q et al., Trovato G et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1007/s12094-026-04560-w | Oey O et al., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026); DOI: 10.1007/s12094-026-04560-w | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000038 | 38 | Optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer — Open Treatment Strategy Question | What is the optimal clinical algorithm for initiating and sequencing optimal duration of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy relative to standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations to maximize overall survival ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does optimal duration of adjuvant immunotherapy compare with standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations re... | Among individuals with metastatic non-small cell lung cancer without targetable driver mutations (including patients with treated brain metastases, autoimmune comorbidity), does optimal duration of adjuvant immunotherapy offer meaningful long-term benefits over standard fixed-duration or unselected dosing regimen in me... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of optimal duration of adju... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Optimal duration of adjuvant immunotherapy | Standard fixed-duration or unselected dosing regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Chen Z et al., Osarogiagbon RU et al., Wang S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.21037/jtd-2025-1389 | Chen Z et al., Journal of thoracic disease (2026); DOI: 10.21037/jtd-2025-1389 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000039 | 39 | Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation — Open Treatment Strategy Question | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, does dynamic treatment adaptation guided by anthracyclines improve overall survival and progression-free or disease-free survival over 60 months compared with standard fixed-duration or unselected dos... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does anthracyclines compare with standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer regarding overall survival and progressio... | What are the real-world benefits and risks of anthracyclines versus standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer over 60 months for patients managing early-stage hormone-receptor-positive HER2-negative breast cancer? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of reassessing ... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | Anthracyclines | Standard fixed-duration or unselected dosing regimen in early-stage hormone-receptor-positive HER2-negative breast cancer | 60 months | comparative_effectiveness | multiple_small_studies | active_scientific_dispute | 5 | frontier | contested | DISPUTED-OPEN | Myrzabay Z et al., Li X et al., Kakimoto S et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.3390/jcm15187303 | Myrzabay Z et al., Journal of clinical medicine (2026); DOI: 10.3390/jcm15187303 | NCT06781281 (OBSERVATIONAL, RECRUITING): NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. (SRC-MED-NCT-0001) | 3 | 5 | true |
UMED-000040 | 40 | The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy — Open Prognosis Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, what is the externally validated prognostic discrimination, calibration, and decision utility of the predictive role of CTDNA and CTCs versus standard clinical risk score without the predictive ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does the predictive role of CTDNA and CTCs compare with standard clinical risk score without the predictive role of CTDNA and CTCs stratification regarding overall survival and progression-free... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does the predictive role of CTDNA and CTCs compare with standard clinical risk score without the predictive role of CTDNA and CTCs stratification for improving overall survival and progression-free or disease-free survival an... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of the predictive role of C... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | prognostic | The Predictive Role of ctDNA and CTCs | Standard clinical risk score without the predictive role of CTDNA and CTCs stratification | 48 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Kakouri AC et al., Lu D et al., Li Z et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3390/ijms27125518 | Kakouri AC et al., International journal of molecular sciences (2026); DOI: 10.3390/ijms27125518 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000041 | 41 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiotherapy for Borderline Resectable Pancreatic Cancer — Open Comparative Effectiveness Question | Among adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, what is the head-to-head comparative effectiveness of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for borderline resectable pancreatic cancer versus standard neoadjuva... | In adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, how does total neoadjuvant therapy compare with standard neoadjuvant chemoradiotherapy regarding overall survival and progression-free or disease-free survival over 36 months? | In patients affected by borderline resectable and locally advanced pancreatic ductal adenocarcinoma, what is the clearest medical evidence on whether total neoadjuvant therapy works better than standard neoadjuvant chemoradiotherapy over 36 months? | In oncology and hematology, managing borderline resectable and locally advanced pancreatic ductal adenocarcinoma (NCCN borderline resectable or locally advanced) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies ... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Borderline resectable and locally advanced pancreatic ductal adenocarcinoma | Adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy | PICOTS | Total Neoadjuvant Therapy | Standard Neoadjuvant Chemoradiotherapy | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Gupta S et al., Zuo H et al., Yeung KTD et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.7759/cureus.115551 | Gupta S et al., Cureus (2026); DOI: 10.7759/cureus.115551 | NCT06944587 (OBSERVATIONAL, RECRUITING): A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advance (SRC-MED-NCT-0043) | 3 | 5 | true |
UMED-000042 | 42 | A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer — Open Safety Question | For patients with colorectal cancer receiving treatment in inpatient ward, ambulatory specialty settings, how does the long-term safety and pharmacovigilance profile of a network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors compare with alternative active comparator or standard dose... | In patients with colorectal cancer, how does a network meta-analysis of endocrine adverse events induced by immune checkpoint compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Can a network meta-analysis of endocrine adverse events induced by immune checkpoint safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with alternative active comparator... | In oncology and hematology, managing colorectal cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of a network meta-analysis of endocrine adverse events induced by i... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Colorectal cancer | Patients with colorectal cancer | PICOTS | A network meta-analysis of endocrine adverse events induced by immune checkpoint | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Chen B et al., Li Z et al., Wang Y et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3389/fimmu.2026.1798732 | Chen B et al., Frontiers in immunology (2026); DOI: 10.3389/fimmu.2026.1798732 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000043 | 43 | Aspirin Versus Other Anticoagulants for the Initial Prevention of Venous Thromboembolism Following Elective Total Hip and Knee Arthroplasty — Open Prevention Question | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, what is the optimal timing and risk threshold for initiating preventive aspirin versus other anticoagulants for the initial prevention of venous thromboembolism following elective ... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does aspirin anticoagulants compare with other anticoagulants regarding recurrent venous thromboembolism and clinically relevant bleeding over 24 months? | Among individuals with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (including thrombocytopenia 25-50 x10^9/L, hepatic or renal dysfunction), does aspirin anticoagulants offer meaningful long-term benefits over other anticoagulants across 24 months? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Aspirin Anticoagulants | Other Anticoagulants | 24 months | population_health | multiple_small_studies | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Borazjani R et al., Gonzalez AG et al., Lan KM et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1016/j.arth.2025.06.032 | Borazjani R et al., The Journal of arthroplasty (2026); DOI: 10.1016/j.arth.2025.06.032 | NCT02285738 (EARLY_PHASE1, COMPLETED): Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (SRC-MED-NCT-0027) | 3 | 5 | true |
UMED-000044 | 44 | Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer — Open Treatment Effectiveness Question | In randomized evaluation of adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, does comparative efficacy and safety of first, second, and third-generation eGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung canc... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does comparative efficacy and safety of first, second compare with standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutation... | What are the real-world benefits and risks of comparative efficacy and safety of first, second versus standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutations over 48 months for patients managing metastatic non-small cell lung cancer without targeta... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of comparative efficacy and... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Comparative efficacy and safety of first, second | Standard-of-care therapy or active control regimen in metastatic non-small cell lung cancer without targetable driver mutations | 48 months | confirmatory_clinical | early_interventional | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Mahato S et al., Chen D et al., Chen S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1186/s43046-026-00414-2 | Mahato S et al., Journal of the Egyptian National Cancer Institute (2026); DOI: 10.1186/s43046-026-00414-2 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000045 | 45 | Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer — Open Safety Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade exposed to comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer versus alternative active comparator or standard dose-monitoring regimen, wha... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does comparative efficacy and safety of post-TKI treatments compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or dis... | For people with metastatic non-small cell lung cancer without targetable driver mutations, how does comparative efficacy and safety of post-TKI treatments compare with alternative active comparator or standard dose-monitoring regimen for improving overall survival and progression-free or disease-free survival and minim... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of comparative efficacy and... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Comparative efficacy and safety of post-TKI treatments | Alternative active comparator or standard dose-monitoring regimen | 48 months | post_authorization | one_pivotal_study | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Wang Y et al., Izadpanah K et al., Liu S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.lungcan.2026.108914 | Wang Y et al., Lung cancer (Amsterdam, Netherlands) (2026); DOI: 10.1016/j.lungcan.2026.108914 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000046 | 46 | Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis — Open Diagnosis Question | Among adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade, does integrating diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis into the diagnostic pathway outperform conventional clinicopathologic, imaging, or la... | In adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade, how does diagnostic and prognostic parameters compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-fr... | In patients affected by immune-related adverse events (myocarditis, pneumonitis, colitis, and endocrinopathies) from checkpoint blockade, what is the clearest medical evidence on whether diagnostic and prognostic parameters works better than conventional clinicopathologic, imaging, or laboratory reference standard over... | In oncology and hematology, managing immune-related adverse events from checkpoint blockade (CTCAE Grade 2-4 immune-related toxicity) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of diagnostic and prognostic... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Immune-related adverse events (myocarditis, pneumonitis, colitis, and endocrinopathies) from checkpoint blockade | Adults with solid tumors developing moderate-to-severe immune-related adverse events during PD-1/PD-L1 or CTLA-4 blockade | PIRD | Diagnostic and prognostic parameters | Conventional clinicopathologic, imaging, or laboratory reference standard | 18 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Lerchner T et al., Lan L et al., Zhou S et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1016/j.ejca.2026.116693 | Lerchner T et al., European journal of cancer (Oxford, England : 1990) (2026); DOI: 10.1016/j.ejca.2026.116693 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000047 | 47 | Efficacy and Safety of Canakinumab Compared With Standard Therapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC) — Open Treatment Strategy Question | Among adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, when can therapy be safely de-escalated, switched, or intensified using canakinumab compared with standard therapy for the treatment of Non-Small cell lung cancer (NSCLC) compared with standard ... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does canakinumab therapy compare with standard therapy regarding overall survival and progression-free or disease-free survival over 48 months? | Can canakinumab therapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 48 months compared with standard therapy for people with metastatic non-small cell lung cancer without targetable ... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safety of c... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PICOTS | Canakinumab Therapy | Standard Therapy | 48 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Izadpanah K et al., Wu X et al., Guo K et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1002/cnr2.70627 | Izadpanah K et al., Cancer reports (Hoboken, N.J.) (2026); DOI: 10.1002/cnr2.70627 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000048 | 48 | Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma — Open Safety Question | What is the causal risk-benefit trade-off between gains in overall survival and progression-free or disease-free survival and cumulative Grade >=3 treatment-related and immune-mediated adverse events over 18 months when using immune-based combinations versus alternative active comparator or standard dose-monitoring reg... | In patients with metastatic hepatocellular carcinoma, how does efficacy compare with alternative active comparator or standard dose-monitoring regimen regarding overall survival and progression-free or disease-free survival over 18 months? | Among individuals with metastatic hepatocellular carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does efficacy offer meaningful long-term benefits over alternative active comparator or standard dose-monitoring regimen across 18 months? | In oncology and hematology, managing metastatic hepatocellular carcinoma (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safety of immune-based combinations in met... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic hepatocellular carcinoma | Patients with metastatic hepatocellular carcinoma | PICOTS | Efficacy | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | de Moura ACC et al., Duan Y et al., Wang W et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12885-026-15893-8 | de Moura ACC et al., BMC cancer (2026); DOI: 10.1186/s12885-026-15893-8 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000049 | 49 | PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups — Open Mechanism Question | In translational human studies of women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how do host-microenvironment or genetic interactions involving PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does PARP inhibitor-based first-line maintenance therapy compare with canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient ... | What are the real-world benefits and risks of PARP inhibitor-based first-line maintenance therapy versus canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer over 24 months for patients managing BRCA-wildtype ... | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (FIGO stage III-IV post-platinum) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | mechanistic | PARP inhibitor-based first-line maintenance therapy | Canonical baseline pathway activity or treatment-sensitive phenotype in BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer | 24 months | fundamental_human_mechanism | mechanistic_evidence_only | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Feng J et al., Panjarwanto DA et al., Gąsowska-Bodnar A et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1884407 | Feng J et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1884407 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000050 | 50 | Predictive value of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy in advanced/recurrent endometrial cancer — Open Prognosis Question | Among patients with advanced/recurrent endometrial cancer, what is the externally validated prognostic discrimination, calibration, and decision utility of PD-L1 expression and dMMR/pMMR status for immune checkpoint inhibitor combined with chemotherapy versus standard clinical risk score without PD-L1 expression and dM... | In patients with advanced/recurrent endometrial cancer, how does PD-L1 expression and dMMR/pMMR status compare with standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification regarding overall survival and progression-free or disease-free survival over 18 months? | For people with advanced/recurrent endometrial cancer, how does PD-L1 expression and dMMR/pMMR status compare with standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-rel... | In oncology and hematology, managing advanced/recurrent endometrial cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of predictive value of PD-L1 expression and dMM... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced/recurrent endometrial cancer | Patients with advanced/recurrent endometrial cancer | prognostic | PD-L1 expression and dMMR/pMMR status | Standard clinical risk score without PD-L1 expression and dMMR/pMMR status stratification | 18 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Lan L et al., Aliouat A et al., Sisca L et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12957-026-04330-6 | Lan L et al., World journal of surgical oncology (2026); DOI: 10.1186/s12957-026-04330-6 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000051 | 51 | Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases — Open Patient Experience Question | In patients with non-small cell lung cancer and brain metastases (including high-risk clinical subgroups, underrepresented age and comorbidity strata), what treatment attributes, lived-experience priorities, and trade-offs between overall survival and progression-free or disease-free survival and Grade >=3 treatment-re... | In patients with non-small cell lung cancer and brain metastases, how does systemic and intracranial activity of antibody-drug conjugates compare with routine clinician-directed care without structured patient-reported decision tool regarding overall survival and progression-free or disease-free survival over 24 months... | In patients affected by non-small cell lung cancer and brain metastases, what is the clearest medical evidence on whether systemic and intracranial activity of antibody-drug conjugates works better than routine clinician-directed care without structured patient-reported decision tool over 24 months? | In oncology and hematology, managing non-small cell lung cancer and brain metastases (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of systemic and intracranial activity... | patient_experience | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Non-small cell lung cancer and brain metastases | Patients with non-small cell lung cancer and brain metastases | qualitative | Systemic and intracranial activity of antibody-drug conjugates | Routine clinician-directed care without structured patient-reported decision tool | 24 months | implementation | observational_only | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Zhou S et al., Zhang YC et al., Chen Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.lungcan.2026.109638 | Zhou S et al., Lung cancer (Amsterdam, Netherlands) (2026); DOI: 10.1016/j.lungcan.2026.109638 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000052 | 52 | Surrogate endpoints for overall survival in extensive-stage small-cell lung cancer — Open Measurement Question | Across multi-center studies of adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how can assay or instrument standardization for surrogate endpoints for overall survival eliminate inter-laboratory variability and improve overall survival and progress... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does surrogate endpoints compare with legacy clinician-rated or unharmonized outcome assessment instrument regarding overall survival and progression-free or disease-free survival over 48 month... | Can surrogate endpoints safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 48 months compared with legacy clinician-rated or unharmonized outcome assessment instrument for people with metas... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (stage IV or recurrent) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of surrogate endpoints for ... | measurement | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | PIRD | Surrogate endpoints | Legacy clinician-rated or unharmonized outcome assessment instrument | 48 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Durer S et al., Schliemann A et al., Kong Y et al. & World Health Organization (WHO) Global Research Agenda | 2,025 | https://doi.org/10.1016/j.esmoop.2025.105843 | Durer S et al., ESMO open (2025); DOI: 10.1016/j.esmoop.2025.105843 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000053 | 53 | Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer — Open Prognosis Question | For adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, can baseline and serial assessment of predictive effectiveness of circulating tumor DNA accurately stratify individual risk of overall survival and progression-free or disease-free survival over 4... | In adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade, how does predictive effectiveness of circulating tumor DNA compare with standard clinical risk score without predictive effectiveness of circulating tumor DNA stratification regarding overall survi... | Among individuals with metastatic non-small cell lung cancer without targetable driver mutations (including patients with treated brain metastases, autoimmune comorbidity), does predictive effectiveness of circulating tumor DNA offer meaningful long-term benefits over standard clinical risk score without predictive eff... | In oncology and hematology, managing metastatic non-small cell lung cancer without targetable driver mutations (early-stage disease) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of predictive effectiveness o... | prognosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Metastatic non-small cell lung cancer without targetable driver mutations | Adults with metastatic non-squamous or squamous NSCLC achieving stable response after 24 months of PD-1/PD-L1 blockade | prognostic | Predictive Effectiveness of Circulating Tumor DNA | Standard clinical risk score without predictive effectiveness of circulating tumor DNA stratification | 48 months | early_clinical | observational_only | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Lu D et al., Durer S et al., Fei Z et al. & World Health Organization (WHO) Global Research Agenda | 2,025 | https://doi.org/10.1200/po-25-00489 | Lu D et al., JCO precision oncology (2025); DOI: 10.1200/po-25-00489 | NCT06465329 (PHASE2, ACTIVE_NOT_RECRUITING): A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer T (SRC-MED-NCT-0006) | 3 | 5 | true |
UMED-000054 | 54 | ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms — Open Screening Question | In population and clinic-based cohorts of adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, does early detection through ATM mutations in myelodysplastic neoplasms, acute myeloid leukemia, and myeloproliferative neoplasms translate... | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, how does MRD-adapted post-remission maintenance versus allogeneic hematopoietic stem cell transplant compare with standard allogeneic HSCT in all intermediate/adverse-risk CR1 pa... | What are the real-world benefits and risks of MRD-adapted post-remission maintenance versus allogeneic hematopoietic stem cell transplant versus standard allogeneic HSCT in all intermediate/adverse-risk CR1 patients over 36 months for patients managing acute myeloid leukemia in first complete remission? | In oncology and hematology, managing acute myeloid leukemia in first complete remission (first complete remission (CR1)) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of ATM mutations in myelodysplastic neopl... | screening | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Acute myeloid leukemia in first complete remission | Adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine | PIRD | MRD-adapted post-remission maintenance versus allogeneic hematopoietic stem cell transplant | Standard allogeneic HSCT in all intermediate/adverse-risk CR1 patients | 36 months | population_health | observational_only | active_scientific_dispute | 3 | hard | contested | DISPUTED-OPEN | Laurindo LO et al., Batyrbekova N et al., Lin J et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1007/s12032-026-03378-4 | Laurindo LO et al., Medical oncology (Northwood, London, England) (2026); DOI: 10.1007/s12032-026-03378-4 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000055 | 55 | Efficacy and Safety of Direct Oral Anticoagulants in Extended Venous Thromboembolism — Open Treatment Strategy Question | For adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation in ambulatory specialty settings, what is the optimal sequencing, dosing threshold, or treatment duration of direct oral anticoagulants versus standard fixed-duration or unselected... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does efficacy compare with standard fixed-duration or unselected dosing regimen in cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignan... | For people with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy, how does efficacy compare with standard fixed-duration or unselected dosing regimen in cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy for improving recurrent ... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | treatment_strategy | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Efficacy | Standard fixed-duration or unselected dosing regimen in cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | 24 months | comparative_effectiveness | multiple_small_studies | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Bacha Z et al., Zuin M et al., Hoxha A et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1097/hpc.0000000000000417 | Bacha Z et al., Critical pathways in cardiology (2026); DOI: 10.1097/hpc.0000000000000417 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000056 | 56 | Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy — Open Treatment Effectiveness Question | In patients evaluated for efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted in oncology and hematology, does therapeutic intervention with guideline-directed clinical management and biomarker stratification in efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted produce ... | In patients evaluated for efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted compare with standard-of-care ther... | In patients affected by efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted, what is the clearest medical evidence on whether guideline-directed clinical management and biomarker stratification in efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted works better than stand... | In oncology and hematology, managing efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of effica... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted | Patients evaluated for efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted in oncology and hematology | PICOTS | Guideline-directed clinical management and biomarker stratification in efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted | Standard-of-care therapy or active control regimen in efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted | 36 months | confirmatory_clinical | early_interventional | broad_consensus_open | 5 | frontier | open | OPEN-VERIFIED | Yu Y et al., Park LJ et al., He J et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1080/10428194.2025.2572420 | Yu Y et al., Leukemia & lymphoma (2026); DOI: 10.1080/10428194.2025.2572420 | NCT07101588 (PHASE4, RECRUITING): Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (SRC-MED-NCT-0012) | 3 | 5 | true |
UMED-000057 | 57 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation — Open Mechanism Question | In patients with hepatocellular carcinoma before and after liver transplantation, what are the primary immunologic, metabolic, or signaling drivers of treatment resistance and disease progression mediated by immune checkpoint inhibitors over 18 months? | In patients with hepatocellular carcinoma before and after liver transplantation, how does immune checkpoint inhibitors compare with canonical baseline pathway activity or treatment-sensitive phenotype in hepatocellular carcinoma before and after liver transplantation regarding overall survival and progression-free or ... | Can immune checkpoint inhibitors safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with canonical baseline pathway activity or treatment-sensitive phenotype in hepatocel... | In oncology and hematology, managing hepatocellular carcinoma before and after liver transplantation (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of immune checkpoint ... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Hepatocellular Carcinoma Before and After Liver Transplantation | Patients with hepatocellular carcinoma before and after liver transplantation | mechanistic | Immune Checkpoint Inhibitors | Canonical baseline pathway activity or treatment-sensitive phenotype in hepatocellular carcinoma before and after liver transplantation | 18 months | fundamental_human_mechanism | mechanistic_evidence_only | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Dituri F et al., Lan LF et al., Xue L et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3390/cancers18081282 | Dituri F et al., Cancers (2026); DOI: 10.3390/cancers18081282 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000058 | 58 | Survival Outcomes With Cadonilimab Versus PD-(L)1 Therapy in Front-Line Gastric Cancer — Open Comparative Effectiveness Question | When treating children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation (including haploidentical or mismatched unrelated donor, pediatric recipients), is survival outcomes with cadonilimab versus PD-(l)1 therapy superior or non-i... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does survival outcomes with cadonilimab compare with PD-(l)1 therapy regarding overall survival and progression-free or disease-free survival over 24 months? | Among individuals with steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (including haploidentical or mismatched unrelated donor, pediatric recipients), does survival outcomes with cadonilimab offer meaningful long-term benefits over PD-(l)1 therapy across 24 months? | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Survival Outcomes With Cadonilimab | PD-(L)1 Therapy | 24 months | comparative_effectiveness | systematic_review_low_certainty | specialist_consensus_open | 1 | bounded | partially_resolved | PARTIAL-PROGRESS | Yu ZK et al., Zhang C et al., Raza MZ et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1002/cnr2.70672 | Yu ZK et al., Cancer reports (Hoboken, N.J.) (2026); DOI: 10.1002/cnr2.70672 | NCT06364319 (PHASE4, NOT_YET_RECRUITING): Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD (SRC-MED-NCT-0037) | 3 | 5 | true |
UMED-000059 | 59 | Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency — Open Health Services Question | Across regional healthcare networks serving women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does decentralized or integrated delivery of treatment for metastatic triple-negative breast cancer with homologous recombination deficiency compare ag... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does antibody-drug conjugate (mirvetuximab soravtansine or trastuzumab deruxtecan) combinations in folate-receptor/HER2-expressing ovarian cancer compare with single-agent non-platinum chemoth... | What are the real-world benefits and risks of antibody-drug conjugate (mirvetuximab soravtansine or trastuzumab deruxtecan) combinations in folate-receptor/HER2-expressing ovarian cancer versus single-agent non-platinum chemotherapy plus bevacizumab over 24 months for patients managing BRCA-wildtype homologous-recombin... | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of... | health_services | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | health_systems | Antibody-drug conjugate (mirvetuximab soravtansine or trastuzumab deruxtecan) combinations in folate-receptor/HER2-expressing ovarian cancer | Single-agent non-platinum chemotherapy plus bevacizumab | 24 months | health_system | observational_only | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Xu H et al., Liang Y et al., Sugiyama R et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1186/s12885-026-15947-x | Xu H et al., BMC cancer (2026); DOI: 10.1186/s12885-026-15947-x | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000060 | 60 | Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis — Open Treatment Effectiveness Question | Among adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation (acute proximal DVT or pulmonary embolism), what is the confirmatory clinical efficacy of rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis c... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does rivaroxaban heparin compare with low-molecular-weight heparin regarding recurrent venous thromboembolism and clinically relevant bleeding over 24 months? | For people with cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy, how does rivaroxaban heparin compare with low-molecular-weight heparin for improving recurrent venous thromboembolism and clinically relevant bleeding and minimizing ISTH major bleeding and clinically releva... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Rivaroxaban heparin | Low-molecular-weight heparin | 24 months | confirmatory_clinical | early_interventional | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Li B et al., Liu J et al., Chang CY et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,025 | https://doi.org/10.3389/fphar.2025.1652779 | Li B et al., Frontiers in pharmacology (2025); DOI: 10.3389/fphar.2025.1652779 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000061 | 61 | Advancing precision immunotherapy in advanced pancreatic cancer — Open Public Health Question | Across high-burden communities of adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, what is the population-level effectiveness and equity impact of public health interventions based on advancing precision immunotherapy versus status-quo population hea... | In adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, how does advancing precision immunotherapy compare with status-quo population health policy without targeted equity intervention regarding overall survival and progression-free or disease-free survi... | In patients affected by borderline resectable and locally advanced pancreatic ductal adenocarcinoma, what is the clearest medical evidence on whether advancing precision immunotherapy works better than status-quo population health policy without targeted equity intervention over 36 months? | In oncology and hematology, managing borderline resectable and locally advanced pancreatic ductal adenocarcinoma (NCCN borderline resectable or locally advanced) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies ... | public_health | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Borderline resectable and locally advanced pancreatic ductal adenocarcinoma | Adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy | health_systems | Advancing precision immunotherapy | Status-quo population health policy without targeted equity intervention | 36 months | population_health | observational_only | broad_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Qi X et al., Gupta S et al., Pillay I et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3389/fimmu.2026.1855859 | Qi X et al., Frontiers in immunology (2026); DOI: 10.3389/fimmu.2026.1855859 | NCT06944587 (OBSERVATIONAL, RECRUITING): A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advance (SRC-MED-NCT-0043) | 3 | 5 | true |
UMED-000062 | 62 | Ambient Particulate Matter Exposure and Risk of Venous Thromboembolism — Open Etiology Question | Through what causal pathways and dose-response relationships does ambient particulate matter exposure and risk of venous thromboembolism drive disease onset and recurrent venous thromboembolism and clinically relevant bleeding over 24 months in adults with active luminal gastrointestinal or urothelial malignancy and ac... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months compare with continued full-dose DOAC or weight-adjusted daltep... | Can reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months safely improve recurrent venous thromboembolism and clinically relevant bleeding and quality of life (anticoagulation treatment burden and health-related quality of life) over 24 months compared with continue... | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | etiology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PECO | Reduced-dose direct oral anticoagulant versus full-dose DOAC or low-molecular-weight heparin after 6 months | Continued full-dose DOAC or weight-adjusted dalteparin/enoxaparin | 24 months | fundamental_human_mechanism | observational_only | specialist_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Correa Lara MVM et al., Loggini A et al., Moran K et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1055/a-2945-4974 | Correa Lara MVM et al., Thrombosis and haemostasis (2026); DOI: 10.1055/a-2945-4974 | NCT07852637 (PHASE4, NOT_YET_RECRUITING): Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (SRC-MED-NCT-0026) | 3 | 5 | true |
UMED-000063 | 63 | Clinical efficacy of immunotherapy in combination of locoregional therapies for advanced hepatocellular carcinoma — Open Mechanism Question | Does target engagement of the biological pathway underlying clinical efficacy of immunotherapy reverse pathological remodeling and improve overall survival and progression-free or disease-free survival over 36 months in adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoim... | In adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoimmunotherapy or dual checkpoint blockade, how does clinical efficacy of immunotherapy compare with canonical baseline pathway activity or treatment-sensitive phenotype in unresectable or metastatic hepatocellular carci... | Among individuals with unresectable or metastatic hepatocellular carcinoma and biliary tract cancer (including Child-Pugh b cirrhosis, portal vein tumor thrombus), does clinical efficacy of immunotherapy offer meaningful long-term benefits over canonical baseline pathway activity or treatment-sensitive phenotype in unr... | In oncology and hematology, managing unresectable or metastatic hepatocellular carcinoma and biliary tract cancer (Child-Pugh A/B, BCLC stage B-C) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of clinical eff... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Unresectable or metastatic hepatocellular carcinoma and biliary tract cancer | Adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoimmunotherapy or dual checkpoint blockade | mechanistic | Clinical efficacy of immunotherapy | Canonical baseline pathway activity or treatment-sensitive phenotype in unresectable or metastatic hepatocellular carcinoma and biliary tract cancer | 36 months | fundamental_human_mechanism | mechanistic_evidence_only | specialist_consensus_open | 4 | very_hard | partially_resolved | PARTIAL-PROGRESS | Chen X et al., Zhao W et al., Zhao Z et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.3389/fimmu.2026.1706375 | Chen X et al., Frontiers in immunology (2026); DOI: 10.3389/fimmu.2026.1706375 | NCT02990351 (OBSERVATIONAL, COMPLETED): Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Tr (SRC-MED-NCT-0031) | 3 | 5 | true |
UMED-000064 | 64 | Comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based regimens for advanced gastric and gastroesophageal junction cancer — Open Safety Question | In patients evaluated for comparative efficacy and safety of first-line immunotherapy- and targeted in oncology and hematology, what mitigation or dose-modification strategy best prevents treatment-limiting Grade >=3 treatment-related and immune-mediated adverse events from comparative efficacy and safety of first-line... | In patients evaluated for comparative efficacy and safety of first-line immunotherapy- and targeted in oncology and hematology, how does comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based compare with alternative active comparator or standard dose-monitoring regimen regarding overal... | What are the real-world benefits and risks of comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based versus alternative active comparator or standard dose-monitoring regimen over 18 months for patients managing comparative efficacy and safety of first-line immunotherapy- and targeted? | In oncology and hematology, managing comparative efficacy and safety of first-line immunotherapy- and targeted (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of comparat... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Comparative efficacy and safety of first-line immunotherapy- and targeted | Patients evaluated for comparative efficacy and safety of first-line immunotherapy- and targeted in oncology and hematology | PICOTS | Comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based | Alternative active comparator or standard dose-monitoring regimen | 18 months | post_authorization | one_pivotal_study | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Wang W et al., de Moura ACC et al., Tamura K et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1186/s12885-026-16434-z | Wang W et al., BMC cancer (2026); DOI: 10.1186/s12885-026-16434-z | NCT04163289 (PHASE1, ACTIVE_NOT_RECRUITING): Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota (SRC-MED-NCT-0051) | 3 | 5 | true |
UMED-000065 | 65 | Effect of adding umbilical cord blood derived stem cells to haploidentical stem cell transplant (haplo-cord) on post-transplant survival and graft-versus-host disease in patients with hematological malignancies — Open Comparative Effectiveness Question | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, does adding umbilical cord blood derived stem cells to haploidentical stem cell transplant (haplo-cord) on post-transplant survival and graft-versus-host disease improv... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare with extracorporeal photopheresis or calcineurin-inhibito... | For people with steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT, how does ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD compare with extracorporeal photopheresis or calcineurin-inhibitor continuation for improving overall survival and ... | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Ruxolitinib vs belumosudil vs axatilimab sequencing or combination in steroid-refractory GVHD | Extracorporeal photopheresis or calcineurin-inhibitor continuation | 24 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 3 | hard | open | BLOCKED-OPEN | Raza MZ et al., Koo RM et al., Ding Y et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1016/j.trim.2026.102431 | Raza MZ et al., Transplant immunology (2026); DOI: 10.1016/j.trim.2026.102431 | NCT04744116 (EARLY_PHASE1, RECRUITING): Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatmen (SRC-MED-NCT-0038) | 3 | 5 | true |
UMED-000066 | 66 | Effectiveness and safety of first-line therapies, dual immunotherapy versus immunotherapy plus targeted therapy in advanced renal cell carcinoma — Open Comparative Effectiveness Question | Among children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, what is the head-to-head comparative effectiveness of first-line therapies, dual immunotherapy versus immunotherapy plus targeted therapy versus immunotherapy plus t... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does first-line therapies, dual immunotherapy compare with immunotherapy plus targeted therapy regarding overall survival and progression-free or disease-free survi... | In patients affected by steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT, what is the clearest medical evidence on whether first-line therapies, dual immunotherapy works better than immunotherapy plus targeted therapy over 24 months? | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | First-line therapies, dual immunotherapy | Immunotherapy plus targeted therapy | 24 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Khadela A et al., Mirza W et al., Xiao X et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1177/10781552261459599 | Khadela A et al., Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2026); DOI: 10.1177/10781552261459599 | NCT00366145 (PHASE3, COMPLETED): Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Gra (SRC-MED-NCT-0039) | 3 | 5 | true |
UMED-000067 | 67 | Efficacy of immunotherapy in older adults with triple-negative breast cancer — Open Natural History Question | Among older adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, what are the transition probabilities between clinical states and cumulative incidence of overall survival and progression-free or disease-free survival over 60 months associated with immunot... | In older adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does immunotherapy compare with standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer regarding overall survival and progres... | Can immunotherapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy of ... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Older adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | natural_history | Immunotherapy | Standard longitudinal clinical surveillance cohort in early-stage hormone-receptor-positive HER2-negative breast cancer | 60 months | early_clinical | observational_only | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Sha C et al., Sun X et al., Van Renne N et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1016/j.jgo.2026.103027 | Sha C et al., Journal of geriatric oncology (2026); DOI: 10.1016/j.jgo.2026.103027 | NCT05558722 (PHASE2, ACTIVE_NOT_RECRUITING): Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER- (SRC-MED-NCT-0002) | 3 | 5 | true |
UMED-000068 | 68 | Emerging Insights into Comparative Genetic Mutations in HPV-Associated and HPV-Independent Cervical Cancer — Open Screening Question | What screening interval and positivity threshold for emerging insights into comparative genetic mutations optimize overall survival and progression-free or disease-free survival and minimize Grade >=3 treatment-related and immune-mediated adverse events compared with symptom-prompted clinical evaluation or current guid... | In patients with HPV-Associated and HPV-Independent cervical cancer, how does emerging insights into comparative genetic mutations compare with symptom-prompted clinical evaluation or current guideline screening schedule regarding overall survival and progression-free or disease-free survival over 24 months? | Among individuals with HPV-Associated and HPV-Independent cervical cancer (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does emerging insights into comparative genetic mutations offer meaningful long-term benefits over symptom-prompted clinical evaluation or current guideline sc... | In oncology and hematology, managing HPV-Associated and HPV-Independent cervical cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of emerging insights into comparat... | screening | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | HPV-Associated and HPV-Independent Cervical Cancer | Patients with HPV-Associated and HPV-Independent cervical cancer | PIRD | Emerging Insights into Comparative Genetic Mutations | Symptom-prompted clinical evaluation or current guideline screening schedule | 24 months | population_health | observational_only | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Santos ABC et al., Wang J et al., Lin X et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.31557/apjcp.2026.27.9.3139 | Santos ABC et al., Asian Pacific journal of cancer prevention : APJCP (2026); DOI: 10.31557/apjcp.2026.27.9.3139 | NCT02285738 (EARLY_PHASE1, COMPLETED): Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (SRC-MED-NCT-0027) | 3 | 5 | true |
UMED-000069 | 69 | Evolution and recent advances in antibody-drug conjugate therapy for lung cancer — Open Diagnosis Question | In patients with antibody-drug conjugate therapy for lung cancer, does diagnostic triage with evolution and recent advances provide superior clinical net benefit over conventional clinicopathologic, imaging, or laboratory reference standard across 24 months? | In patients with antibody-drug conjugate therapy for lung cancer, how does evolution compare with conventional clinicopathologic, imaging, or laboratory reference standard regarding overall survival and progression-free or disease-free survival over 24 months? | What are the real-world benefits and risks of evolution versus conventional clinicopathologic, imaging, or laboratory reference standard over 24 months for patients managing antibody-drug conjugate therapy for lung cancer? | In oncology and hematology, managing antibody-drug conjugate therapy for lung cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of evolution and recent advances in a... | diagnosis | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Antibody-drug conjugate therapy for lung cancer | Patients with antibody-drug conjugate therapy for lung cancer | PIRD | Evolution | Conventional clinicopathologic, imaging, or laboratory reference standard | 24 months | biomarker_discovery | multiple_small_studies | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Chen Y et al., Zhou S et al., Kemik F et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fonc.2026.1793949 | Chen Y et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1793949 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000070 | 70 | First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma — Open Natural History Question | Across longitudinal cohorts of patients with advanced merkel cell carcinoma, what is the natural trajectory, progression rate, and determinant profile of overall survival and progression-free or disease-free survival over 24 months in relation to first-line ipilimumab plus nivolumab versus standard longitudinal clinica... | In patients with advanced merkel cell carcinoma, how does first-line ipilimumab plus nivolumab compare with standard longitudinal clinical surveillance cohort in advanced merkel cell carcinoma regarding overall survival and progression-free or disease-free survival over 24 months? | For people with advanced merkel cell carcinoma, how does first-line ipilimumab plus nivolumab compare with standard longitudinal clinical surveillance cohort in advanced merkel cell carcinoma for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immu... | In oncology and hematology, managing advanced merkel cell carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of first-line ipilimumab plus nivolumab in advanced me... | natural_history | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced merkel cell carcinoma | Patients with advanced merkel cell carcinoma | natural_history | First-line ipilimumab plus nivolumab | Standard longitudinal clinical surveillance cohort in advanced merkel cell carcinoma | 24 months | early_clinical | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Ramadoss T et al., Furubayashi N et al., Liu H et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1007/s00262-026-04313-2 | Ramadoss T et al., Cancer immunology, immunotherapy : CII (2026); DOI: 10.1007/s00262-026-04313-2 | NCT01490723 (PHASE2, COMPLETED): Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) (SRC-MED-NCT-0020) | 3 | 5 | true |
UMED-000071 | 71 | Liver Transplantation Versus Resection for Single-Nodule Hepatocellular Carcinoma — Open Comparative Effectiveness Question | Among adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoimmunotherapy or dual checkpoint blockade, what is the head-to-head comparative effectiveness of liver transplantation versus resection for Single-Nodule hepatocellular carcinoma versus resection for achieving superi... | In adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoimmunotherapy or dual checkpoint blockade, how does liver transplantation compare with resection regarding overall survival and progression-free or disease-free survival over 36 months? | In patients affected by unresectable or metastatic hepatocellular carcinoma and biliary tract cancer, what is the clearest medical evidence on whether liver transplantation works better than resection over 36 months? | In oncology and hematology, managing unresectable or metastatic hepatocellular carcinoma and biliary tract cancer (Child-Pugh A/B, BCLC stage B-C) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of liver transp... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Unresectable or metastatic hepatocellular carcinoma and biliary tract cancer | Adults with unresectable hepatocellular carcinoma or cholangiocarcinoma receiving first-line chemoimmunotherapy or dual checkpoint blockade | PICOTS | Liver Transplantation | Resection | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Rosa-Sánchez C et al., Chen X et al., Nezi G et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1002/jhbp.70182 | Rosa-Sánchez C et al., Journal of hepato-biliary-pancreatic sciences (2026); DOI: 10.1002/jhbp.70182 | NCT02990351 (OBSERVATIONAL, COMPLETED): Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Tr (SRC-MED-NCT-0031) | 3 | 5 | true |
UMED-000072 | 72 | Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma — Open Classification Question | For patients with Favorable-Risk metastatic renal cell carcinoma, do disease subtypes defined by Long-Term survival outcomes of immune checkpoint inhibitor-based combination therapies exhibit distinct treatment responses and overall survival and progression-free or disease-free survival trajectories over 18 months comp... | In patients with Favorable-Risk metastatic renal cell carcinoma, how does Long-Term survival outcomes of immune checkpoint inhibitor-based combination therapies compare with conventional clinicopathologic staging and consensus taxonomy regarding overall survival and progression-free or disease-free survival over 18 mon... | Can Long-Term survival outcomes of immune checkpoint inhibitor-based combination therapies safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 18 months compared with conventional clinicopat... | In oncology and hematology, managing Favorable-Risk metastatic renal cell carcinoma (metastatic or advanced stage) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Long-Term survival outcomes of immune checkp... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Favorable-Risk Metastatic Renal Cell Carcinoma | Patients with Favorable-Risk metastatic renal cell carcinoma | prognostic | Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies | Conventional clinicopathologic staging and consensus taxonomy | 18 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Zhou S et al., Takahashi H et al., Sugiyama K et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1016/j.clgc.2026.102593 | Zhou S et al., Clinical genitourinary cancer (2026); DOI: 10.1016/j.clgc.2026.102593 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000073 | 73 | Neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherapy in resectable or borderline resectable PDAC — Open Comparative Effectiveness Question | When treating children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation (including haploidentical or mismatched unrelated donor, pediatric recipients), is neoadjuvant therapy versus upfront surgery followed by adjuvant chemotherap... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does neoadjuvant therapy compare with upfront surgery followed by adjuvant chemotherapy regarding overall survival and progression-free or disease-free survival ove... | Among individuals with steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (including haploidentical or mismatched unrelated donor, pediatric recipients), does neoadjuvant therapy offer meaningful long-term benefits over upfront surgery followed by adjuvant chemotherapy across 24 months... | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | comparative_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Neoadjuvant therapy | Upfront surgery followed by adjuvant chemotherapy | 24 months | comparative_effectiveness | systematic_review_low_certainty | specialist_consensus_open | 1 | bounded | partially_resolved | PARTIAL-PROGRESS | de Jesus VHF et al., Xu T et al., Ghidini M et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1177/17588359261449077 | de Jesus VHF et al., Therapeutic advances in medical oncology (2026); DOI: 10.1177/17588359261449077 | NCT06364319 (PHASE4, NOT_YET_RECRUITING): Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD (SRC-MED-NCT-0037) | 3 | 5 | true |
UMED-000074 | 74 | PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer — Open Methodology Question | When validating predictive or causal claims regarding PARP inhibitors and the risk of serum creatinine elevation in women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, what external transportability and bias-quantification standards are required to es... | In women with advanced high-Grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy, how does PARP inhibitors compare with conventional unadjusted analysis or traditional fixed-sample trial design regarding overall survival and progression-free or disease-free survival over 24 mon... | What are the real-world benefits and risks of PARP inhibitors versus conventional unadjusted analysis or traditional fixed-sample trial design over 24 months for patients managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer? | In oncology and hematology, managing BRCA-wildtype homologous-recombination-proficient advanced high-Grade serous ovarian cancer (FIGO stage III-IV post-platinum) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | BRCA-wildtype homologous-recombination-proficient advanced high-grade serous ovarian cancer | Women with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after platinum chemotherapy | PICOTS | PARP Inhibitors | Conventional unadjusted analysis or traditional fixed-sample trial design | 24 months | confirmatory_clinical | systematic_review_low_certainty | active_scientific_dispute | 1 | bounded | contested | DISPUTED-OPEN | Gąsowska-Bodnar A et al., Santos LP et al., Iguchi K et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3390/cancers18081226 | Gąsowska-Bodnar A et al., Cancers (2026); DOI: 10.3390/cancers18081226 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000075 | 75 | Prognostic Value of the C-Reactive Protein-Albumin-Lymphocyte Index in Hepatobiliary and Pancreatic Cancers — Open Rehabilitation Question | In patients with hepatobiliary and pancreatic cancers, does structured rehabilitation incorporating the C-Reactive Protein-Albumin-Lymphocyte index improve functional recovery and overall survival and progression-free or disease-free survival over 24 months compared with usual physical and functional care without struc... | In patients with hepatobiliary and pancreatic cancers, how does C-Reactive Protein-Albumin-Lymphocyte index compare with usual physical and functional care without structured rehabilitation pathway regarding overall survival and progression-free or disease-free survival over 24 months? | For people with hepatobiliary and pancreatic cancers, how does C-Reactive Protein-Albumin-Lymphocyte index compare with usual physical and functional care without structured rehabilitation pathway for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and... | In oncology and hematology, managing hepatobiliary and pancreatic cancers (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of prognostic value of the C-Reactive Protein-Al... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Hepatobiliary and Pancreatic Cancers | Patients with hepatobiliary and pancreatic cancers | PICOTS | C-Reactive Protein-Albumin-Lymphocyte Index | Usual physical and functional care without structured rehabilitation pathway | 24 months | comparative_effectiveness | multiple_small_studies | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Shamohammadi M et al., Rayyan Y et al., Liu X et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1007/s12029-026-01603-x | Shamohammadi M et al., Journal of gastrointestinal cancer (2026); DOI: 10.1007/s12029-026-01603-x | NCT02285738 (EARLY_PHASE1, COMPLETED): Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (SRC-MED-NCT-0027) | 3 | 5 | true |
UMED-000076 | 76 | Safety and efficacy of fecal microbial transplantation for the prevention and treatment of acute graft-versus-host disease — Open Methodology Question | For evaluating safety and efficacy of fecal microbial transplantation for the prevention and treatment of acute graft-versus-host disease versus conventional unadjusted analysis or traditional fixed-sample trial design in children and adults with steroid-refractory acute or chronic graft-versus-host disease following a... | In children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation, how does safety and efficacy of fecal microbial transplantation compare with conventional unadjusted analysis or traditional fixed-sample trial design regarding overall... | In patients affected by steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT, what is the clearest medical evidence on whether safety and efficacy of fecal microbial transplantation works better than conventional unadjusted analysis or traditional fixed-sample trial design over 24 months... | In oncology and hematology, managing steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT (NIH moderate-to-severe cGVHD or Grade III-IV aGVHD) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse eve... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Steroid-refractory acute and chronic graft-versus-host disease after allogeneic HSCT | Children and adults with steroid-refractory acute or chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation | PICOTS | Safety and efficacy of fecal microbial transplantation | Conventional unadjusted analysis or traditional fixed-sample trial design | 24 months | confirmatory_clinical | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Zhang L et al., Yang K et al., Chen M et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.3389/fmicb.2026.1802260 | Zhang L et al., Frontiers in microbiology (2026); DOI: 10.3389/fmicb.2026.1802260 | NCT00366145 (PHASE3, COMPLETED): Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Gra (SRC-MED-NCT-0039) | 3 | 5 | true |
UMED-000077 | 77 | Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer — Open Supportive Palliative Question | Among adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy and their caregivers, does a multidisciplinary supportive pathway centered on stage-specific associations of HER2 overexpression with clinical and pathological features reduce acute care utilization... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does stage-specific associations of HER2 overexpression compare with usual symptom-directed care without integrated supportive pathway regarding overall survival and progression-free or disease-fr... | Can stage-specific associations of HER2 overexpression safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with usual symptom-directed care without integrated supportive p... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of stage-specif... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | Stage-specific associations of HER2 overexpression | Usual symptom-directed care without integrated supportive pathway | 60 months | comparative_effectiveness | systematic_review_low_certainty | specialist_consensus_open | 3 | hard | open | OPEN-VERIFIED | Guo C et al., Myrzabay Z et al., de Moraes FCA et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1007/s11255-026-05110-7 | Guo C et al., International urology and nephrology (2026); DOI: 10.1007/s11255-026-05110-7 | NCT03078751 (PHASE2, COMPLETED): Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Ca (SRC-MED-NCT-0003) | 3 | 5 | true |
UMED-000078 | 78 | Treatment-related deaths with immune checkpoint inhibitor-based combinations versus tyrosine kinase inhibitor monotherapy in hepatocellular carcinoma — Open Mechanism Question | Does target engagement of the biological pathway underlying treatment-related deaths with immune checkpoint inhibitor-based combinations versus tyrosine kinase inhibitor monotherapy reverse pathological remodeling and improve overall survival and progression-free or disease-free survival over 18 months in patients with... | In patients with hepatocellular carcinoma, how does treatment-related deaths with immune checkpoint inhibitor-based combinations compare with tyrosine kinase inhibitor monotherapy regarding overall survival and progression-free or disease-free survival over 18 months? | Among individuals with hepatocellular carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does treatment-related deaths with immune checkpoint inhibitor-based combinations offer meaningful long-term benefits over tyrosine kinase inhibitor monotherapy across 18 months? | In oncology and hematology, managing hepatocellular carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of treatment-related deaths with immune checkpoint inhibitor... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Hepatocellular carcinoma | Patients with hepatocellular carcinoma | mechanistic | Treatment-related deaths with immune checkpoint inhibitor-based combinations | Tyrosine kinase inhibitor monotherapy | 18 months | fundamental_human_mechanism | mechanistic_evidence_only | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Trovato G et al., Minami S et al., Oey O et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1016/j.critrevonc.2026.105350 | Trovato G et al., Critical reviews in oncology/hematology (2026); DOI: 10.1016/j.critrevonc.2026.105350 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000079 | 79 | Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer — Open Treatment Effectiveness Question | In randomized evaluation of adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, does comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer achieve clinically meaningful gains in overall sur... | In adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy, how does comparison of efficacy and safety between neoadjuvant therapy and surgical treatment compare with standard-of-care therapy or active control regimen in borderline resectable and locally adv... | What are the real-world benefits and risks of comparison of efficacy and safety between neoadjuvant therapy and surgical treatment versus standard-of-care therapy or active control regimen in borderline resectable and locally advanced pancreatic ductal adenocarcinoma over 36 months for patients managing borderline rese... | In oncology and hematology, managing borderline resectable and locally advanced pancreatic ductal adenocarcinoma (NCCN borderline resectable or locally advanced) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies ... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Borderline resectable and locally advanced pancreatic ductal adenocarcinoma | Adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy | PICOTS | Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment | Standard-of-care therapy or active control regimen in borderline resectable and locally advanced pancreatic ductal adenocarcinoma | 36 months | confirmatory_clinical | early_interventional | active_scientific_dispute | 4 | very_hard | contested | DISPUTED-OPEN | Zuo H et al., Hong SS et al., Garcia L et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,025 | https://doi.org/10.1097/md.0000000000044570 | Zuo H et al., Medicine (2025); DOI: 10.1097/md.0000000000044570 | NCT06944587 (OBSERVATIONAL, RECRUITING): A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advance (SRC-MED-NCT-0043) | 3 | 5 | true |
UMED-000080 | 80 | Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma — Open Patient Experience Question | Among adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, how does care delivery incorporating unveiling the prognostic significance of BCL6+/CD10+ mantle cell lymphoma compare with autologous CAR-T cell infusion or continuous kinase inhibition in improving... | In adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma, how does CD20xCD3 bispecific antibodies (mosunetuzumab/epcoritamab/glofitamab) vs non-covalent pirtobrutinib or CAR-T therapy compare with autologous CAR-T cell infusion or continuous kinase inhibition ... | For people with relapsed or refractory follicular and mantle cell lymphoma, how does CD20xCD3 bispecific antibodies (mosunetuzumab/epcoritamab/glofitamab) vs non-covalent pirtobrutinib or CAR-T therapy compare with autologous CAR-T cell infusion or continuous kinase inhibition for improving overall survival and progres... | In oncology and hematology, managing relapsed or refractory follicular and mantle cell lymphoma (POD24 or BTK-inhibitor exposed) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of unveiling the prognostic signi... | patient_experience | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed or refractory follicular and mantle cell lymphoma | Adults with early-progressing follicular lymphoma (POD24) or covalent BTK-inhibitor-relapsed mantle cell lymphoma | qualitative | CD20xCD3 bispecific antibodies (mosunetuzumab/epcoritamab/glofitamab) vs non-covalent pirtobrutinib or CAR-T therapy | Autologous CAR-T cell infusion or continuous kinase inhibition | 36 months | implementation | observational_only | broad_consensus_open | 1 | bounded | open | BLOCKED-OPEN | Castillo DR et al., Zhang N et al., Wang Y et al. & Cochrane Collaboration Evidence Synthesis Group | 2,023 | https://doi.org/10.3390/ijms241210207 | Castillo DR et al., International journal of molecular sciences (2023); DOI: 10.3390/ijms241210207 | NCT00293345 (PHASE1, COMPLETED): 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (SRC-MED-NCT-0047) | 3 | 5 | true |
UMED-000081 | 81 | Prophylactic Anticoagulation for the Prevention of Catheter-Related Thrombosis in Adult Cancer Patients with Long-Term Central Venous Catheters — Open Prevention Question | Among adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation (including thrombocytopenia 25-50 x10^9/L, hepatic or renal dysfunction), what is the preventive efficacy and number needed to treat of prophylactic anticoagulation for the preve... | In adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation, how does prophylactic anticoagulation compare with routine risk-factor modification or standard surveillance without targeted prophylaxis regarding recurrent venous thromboembolism... | In patients affected by cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy, what is the clearest medical evidence on whether prophylactic anticoagulation works better than routine risk-factor modification or standard surveillance without targeted prophylaxis over 24 months? | In oncology and hematology, managing cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy (acute proximal DVT or pulmonary embolism) requires balancing recurrent venous thromboembolism and clinically relevant bleeding and ISTH major bleeding and clinically relevant non-major b... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Cancer-associated venous thromboembolism in active gastrointestinal or genitourinary malignancy | Adults with active luminal gastrointestinal or urothelial malignancy and acute cancer-associated VTE requiring extended anticoagulation | PICOTS | Prophylactic Anticoagulation | Routine risk-factor modification or standard surveillance without targeted prophylaxis | 24 months | population_health | multiple_small_studies | broad_consensus_open | 5 | frontier | open | OPEN-VERIFIED | Kania J et al., Salinas-Mendoza S et al., Zhang Y et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.3390/jcm15145566 | Kania J et al., Journal of clinical medicine (2026); DOI: 10.3390/jcm15145566 | NCT02285738 (EARLY_PHASE1, COMPLETED): Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (SRC-MED-NCT-0027) | 3 | 5 | true |
UMED-000082 | 82 | Associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes in patients with advanced esophageal cancer — Open Classification Question | For patients with advanced esophageal cancer, do disease subtypes defined by associations of PD-L1 expression status, tumor histology and patient ethnic background with immunotherapy outcomes exhibit distinct treatment responses and overall survival and progression-free or disease-free survival trajectories over 24 mon... | In patients with advanced esophageal cancer, how does associations of PD-L1 expression status, tumor histology compare with conventional clinicopathologic staging and consensus taxonomy regarding overall survival and progression-free or disease-free survival over 24 months? | Can associations of PD-L1 expression status, tumor histology safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with conventional clinicopathologic staging and consensus ... | In oncology and hematology, managing advanced esophageal cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of associations of PD-L1 expression status, tumor histolog... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced esophageal cancer | Patients with advanced esophageal cancer | prognostic | Associations of PD-L1 expression status, tumor histology | Conventional clinicopathologic staging and consensus taxonomy | 24 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Cai X et al., Marhamati S et al., Bai L et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3389/fphar.2026.1879335 | Cai X et al., Frontiers in pharmacology (2026); DOI: 10.3389/fphar.2026.1879335 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000083 | 83 | Biomarker-Stratified Efficacy of Immune Checkpoint Inhibitors in Locally Advanced Head and Neck Squamous Cell Carcinoma — Open Treatment Effectiveness Question | What is the magnitude and durability of treatment benefit from Biomarker-Stratified efficacy of immune checkpoint inhibitors versus standard-of-care therapy or active control regimen in locally advanced head and neck squamous cell carcinoma on overall survival and progression-free or disease-free survival over 18 month... | In patients with locally advanced head and neck squamous cell carcinoma, how does Biomarker-Stratified efficacy of immune checkpoint inhibitors compare with standard-of-care therapy or active control regimen in locally advanced head and neck squamous cell carcinoma regarding overall survival and progression-free or dis... | Among individuals with locally advanced head and neck squamous cell carcinoma (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does Biomarker-Stratified efficacy of immune checkpoint inhibitors offer meaningful long-term benefits over standard-of-care therapy or active control regi... | In oncology and hematology, managing locally advanced head and neck squamous cell carcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Biomarker-Stratified effica... | treatment_effectiveness | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Locally Advanced Head and Neck Squamous Cell Carcinoma | Patients with locally advanced head and neck squamous cell carcinoma | PICOTS | Biomarker-Stratified Efficacy of Immune Checkpoint Inhibitors | Standard-of-care therapy or active control regimen in locally advanced head and neck squamous cell carcinoma | 18 months | confirmatory_clinical | early_interventional | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Srinivasmurthy R et al., Xu S et al., Wu C et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.3390/cancers18111679 | Srinivasmurthy R et al., Cancers (2026); DOI: 10.3390/cancers18111679 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000084 | 84 | Deciphering survival disparities in endometrial cancer in Locally advanced mismatch-repair-proficient rectal adenocarcinoma (Mechanism) | In translational human studies of adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, how do host-microenvironment or genetic interactions involving deciphering survival disparities govern overall survival and progression-free or disease-free survival over 60 months? | In adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy, how does deciphering survival disparities compare with canonical baseline pathway activity or treatment-sensitive phenotype in locally advanced mismatch-repair-proficient rectal adenocarcinoma regarding overall sur... | What are the real-world benefits and risks of deciphering survival disparities versus canonical baseline pathway activity or treatment-sensitive phenotype in locally advanced mismatch-repair-proficient rectal adenocarcinoma over 60 months for patients managing locally advanced mismatch-repair-proficient rectal adenocar... | In oncology and hematology, managing locally advanced mismatch-repair-proficient rectal adenocarcinoma (clinical stage T3-T4 or node-positive) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of deciphering surv... | mechanism | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Locally advanced mismatch-repair-proficient rectal adenocarcinoma | Adults with locally advanced distal or mid-rectal adenocarcinoma undergoing total neoadjuvant therapy | mechanistic | Deciphering survival disparities | Canonical baseline pathway activity or treatment-sensitive phenotype in locally advanced mismatch-repair-proficient rectal adenocarcinoma | 60 months | fundamental_human_mechanism | mechanistic_evidence_only | active_scientific_dispute | 4 | very_hard | contested | DISPUTED-OPEN | Jumaah AS et al., Hu S et al., Li Y et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.1007/s12094-026-04407-4 | Jumaah AS et al., Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2026); DOI: 10.1007/s12094-026-04407-4 | NCT07175636 (PHASE2, NOT_YET_RECRUITING): QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer (SRC-MED-NCT-0014) | 3 | 5 | true |
UMED-000085 | 85 | Effects of donor killer-cell immunoglobulin-like receptor genotypes on clinical outcome after allogeneic hematopoietic stem cell transplantation — Open Health Services Question | In health systems managing adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does organizing care delivery around donor killer-cell immunoglobulin-like receptor genotypes on clinical outcome after allogeneic hematopoietic stem cell transplantation c... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does donor killer-cell immunoglobulin-like receptor genotypes compare with conventional specialty or hospital-centered care delivery model regarding overall survival and progression-free or diseas... | For people with early-stage hormone-receptor-positive HER2-negative breast cancer, how does donor killer-cell immunoglobulin-like receptor genotypes compare with conventional specialty or hospital-centered care delivery model for improving overall survival and progression-free or disease-free survival and minimizing Gr... | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of effects of d... | health_services | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | health_systems | Donor killer-cell immunoglobulin-like receptor genotypes | Conventional specialty or hospital-centered care delivery model | 60 months | health_system | observational_only | broad_consensus_open | 1 | bounded | open | BLOCKED-OPEN | Huang Y et al., Ateiwi YA et al., Minematsu N et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.3389/fimmu.2026.1856878 | Huang Y et al., Frontiers in immunology (2026); DOI: 10.3389/fimmu.2026.1856878 | NCT03078751 (PHASE2, COMPLETED): Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Ca (SRC-MED-NCT-0003) | 3 | 5 | true |
UMED-000086 | 86 | Efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) in Relapsed or refractory multiple myeloma (Methodology) | For evaluating efficacy and safety profile of busulfan plus low-dose melphalan (BUMEL) versus high-dose melphalan (MEL200) as a conditioning regimen for autologous hematopoietic stem cell transplantation (auto-HSCT) versus high-dose melphalan (MEL200) as a conditioning regimen in adults with triple-class exposed relaps... | In adults with triple-class exposed relapsed or refractory multiple myeloma eligible for t-cell redirecting therapy, how does busulfan plus low-dose melphalan (BUMEL) compare with high-dose melphalan (MEL200) as a conditioning regimen regarding overall survival and progression-free or disease-free survival over 36 mont... | In patients affected by relapsed or refractory multiple myeloma, what is the clearest medical evidence on whether busulfan plus low-dose melphalan (BUMEL) works better than high-dose melphalan (MEL200) as a conditioning regimen over 36 months? | In oncology and hematology, managing relapsed or refractory multiple myeloma (triple-class exposed relapsed/refractory) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy and safety profile of busulfan... | methodology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Relapsed or refractory multiple myeloma | Adults with triple-class exposed relapsed or refractory multiple myeloma eligible for T-cell redirecting therapy | PICOTS | Busulfan plus low-dose melphalan (BUMEL) | High-dose melphalan (MEL200) as a conditioning regimen | 36 months | confirmatory_clinical | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Maqbool S et al., Sáez-Marín AJ et al., Hamm AF et al. & National Institute for Health and Care Excellence (NICE) Guidance & Research Recommendations | 2,026 | https://doi.org/10.1080/17474086.2026.2649831 | Maqbool S et al., Expert review of hematology (2026); DOI: 10.1080/17474086.2026.2649831 | NCT06868654 (PHASE3, ACTIVE_NOT_RECRUITING): China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and (SRC-MED-NCT-0008) | 3 | 5 | true |
UMED-000087 | 87 | FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer — Open Public Health Question | In population surveillance of patients with bladder cancer, how do social determinants and policy implementation of FGFR3 alterations and Nectin-4 expression as therapeutic biomarkers modify overall survival and progression-free or disease-free survival and disease burden over 60 months compared with status-quo populat... | In patients with bladder cancer, how does FGFR3 alterations compare with status-quo population health policy without targeted equity intervention regarding overall survival and progression-free or disease-free survival over 60 months? | Can FGFR3 alterations safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 60 months compared with status-quo population health policy without targeted equity intervention for people with bla... | In oncology and hematology, managing bladder cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of FGFR3 alterations and Nectin-4 expression as therapeutic biomarkers... | public_health | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Bladder Cancer | Patients with bladder cancer | health_systems | FGFR3 Alterations | Status-quo population health policy without targeted equity intervention | 60 months | population_health | observational_only | specialist_consensus_open | 2 | moderate | open | OPEN-VERIFIED | Antonov P et al., Miyajima K et al., Sukati S et al. & Patient-Centered Outcomes Research Institute (PCORI) & International Specialty Society Task Force | 2,026 | https://doi.org/10.3390/ijms27115007 | Antonov P et al., International journal of molecular sciences (2026); DOI: 10.3390/ijms27115007 | NCT06003387 (PHASE3, RECRUITING): Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophili (SRC-MED-NCT-0058) | 3 | 5 | true |
UMED-000088 | 88 | Genetics of thrombotic thrombocytopenic purpura — Open Rehabilitation Question | In patients with thrombotic thrombocytopenic purpura, how does combining neuroplastic or physical conditioning via genetics of thrombotic thrombocytopenic purpura compare against usual physical and functional care without structured rehabilitation pathway in restoring mobility, function, and annualized bleeding or cris... | In patients with thrombotic thrombocytopenic purpura, how does genetics of thrombotic thrombocytopenic purpura compare with usual physical and functional care without structured rehabilitation pathway regarding annualized bleeding or crisis rate, hemoglobin stabilization, and event-free survival over 18 months? | Among individuals with thrombotic thrombocytopenic purpura (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does genetics of thrombotic thrombocytopenic purpura offer meaningful long-term benefits over usual physical and functional care without structured rehabilitation pathway acr... | In oncology and hematology, managing thrombotic thrombocytopenic purpura (clinically characterized human cohort) requires balancing annualized bleeding or crisis rate, hemoglobin stabilization, and event-free survival and thromboembolic events, hemolysis or bleeding breakthroughs, and immunogenicity. Studies of genetic... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Thrombotic thrombocytopenic purpura | Patients with thrombotic thrombocytopenic purpura | PICOTS | Genetics of thrombotic thrombocytopenic purpura | Usual physical and functional care without structured rehabilitation pathway | 18 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Carter MA et al., Peng JY et al., Halkidis K et al. & Campbell Collaboration & Joanna Briggs Institute Evidence Synthesis | 2,026 | https://doi.org/10.1016/j.jtha.2026.01.022 | Carter MA et al., Journal of thrombosis and haemostasis : JTH (2026); DOI: 10.1016/j.jtha.2026.01.022 | NCT05813418 (NA, RECRUITING): Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients U (SRC-MED-NCT-0050) | 3 | 5 | true |
UMED-000089 | 89 | Leukotriene receptor antagonist drugs as potential chemopreventive agents — Open Prevention Question | Across community and clinical cohorts of adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, does sustained preventive intervention with leukotriene receptor antagonist drugs as potential chemopreventive agents reduce long-term overall survival and progre... | In adults with resected stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy, how does CTDNA-guided treatment intensification or de-escalation compare with standard clinical and radiographic surveillance without CTDNA-directed changes regarding overall survival and progression-... | What are the real-world benefits and risks of CTDNA-guided treatment intensification or de-escalation versus standard clinical and radiographic surveillance without CTDNA-directed changes over 60 months for patients managing early-stage hormone-receptor-positive HER2-negative breast cancer? | In oncology and hematology, managing early-stage hormone-receptor-positive HER2-negative breast cancer (stage II-III post-neoadjuvant or adjuvant) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of leukotriene ... | prevention | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Early-stage hormone-receptor-positive HER2-negative breast cancer | Adults with resected Stage II-III HR+/HER2- breast cancer receiving adjuvant endocrine and CDK4/6 inhibitor therapy | PICOTS | ctDNA-guided treatment intensification or de-escalation | Standard clinical and radiographic surveillance without ctDNA-directed changes | 60 months | population_health | multiple_small_studies | active_scientific_dispute | 5 | frontier | contested | DISPUTED-OPEN | de Moraes FCA et al., Guo C et al., Huang Y et al. & James Lind Alliance Priority Setting Partnership | 2,026 | https://doi.org/10.1016/j.plefa.2026.102732 | de Moraes FCA et al., Prostaglandins, leukotrienes, and essential fatty acids (2026); DOI: 10.1016/j.plefa.2026.102732 | NCT03078751 (PHASE2, COMPLETED): Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Ca (SRC-MED-NCT-0003) | 3 | 5 | true |
UMED-000090 | 90 | Low-Dose Post-Transplant Cyclophosphamide in Haploidentical Stem Cell Transplantation — Open Supportive Palliative Question | For patients with haploidentical stem cell transplantation experiencing symptom burden, does integrated supportive or palliative care via Low-Dose Post-Transplant cyclophosphamide improve EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden and overall survival and progression-free or disease-fr... | In patients with haploidentical stem cell transplantation, how does Low-Dose Post-Transplant cyclophosphamide compare with usual symptom-directed care without integrated supportive pathway regarding overall survival and progression-free or disease-free survival over 36 months? | For people with haploidentical stem cell transplantation, how does Low-Dose Post-Transplant cyclophosphamide compare with usual symptom-directed care without integrated supportive pathway for improving overall survival and progression-free or disease-free survival and minimizing Grade >=3 treatment-related and immune-m... | In oncology and hematology, managing haploidentical stem cell transplantation (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Low-Dose Post-Transplant cyclophosphamide... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Haploidentical Stem Cell Transplantation | Patients with haploidentical stem cell transplantation | PICOTS | Low-Dose Post-Transplant Cyclophosphamide | Usual symptom-directed care without integrated supportive pathway | 36 months | comparative_effectiveness | systematic_review_low_certainty | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Shafqat A et al., Liu M et al., Rodriguez-Rodriguez S et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.1016/j.jtct.2025.11.034 | Shafqat A et al., Transplantation and cellular therapy (2026); DOI: 10.1016/j.jtct.2025.11.034 | NCT02789254 (PHASE1/PHASE2, COMPLETED): FLYSYN in MRD Positive AML (SRC-MED-NCT-0010) | 3 | 5 | true |
UMED-000091 | 91 | PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy — Open Classification Question | Among patients with advanced NSCLC previously treated with immunotherapy, can a reproducible subphenotype taxonomy based on PD-(l)1 containing rechallenge strategies resolve clinical heterogeneity and improve overall survival and progression-free or disease-free survival stratification over 24 months versus conventiona... | In patients with advanced NSCLC previously treated with immunotherapy, how does PD-(l)1 containing rechallenge strategies compare with conventional clinicopathologic staging and consensus taxonomy regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by advanced NSCLC previously treated with immunotherapy, what is the clearest medical evidence on whether PD-(l)1 containing rechallenge strategies works better than conventional clinicopathologic staging and consensus taxonomy over 24 months? | In oncology and hematology, managing advanced NSCLC previously treated with immunotherapy (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of PD-(l)1 containing rechalleng... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced NSCLC previously treated with immunotherapy | Patients with advanced NSCLC previously treated with immunotherapy | prognostic | PD-(L)1 containing rechallenge strategies | Conventional clinicopathologic staging and consensus taxonomy | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Marinelli D et al., Nitta H et al., Madár I et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ctrv.2026.103159 | Marinelli D et al., Cancer treatment reviews (2026); DOI: 10.1016/j.ctrv.2026.103159 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000092 | 92 | Prognostic implications of myelodysplasia-related gene mutations in NPM1 -mutated acute myeloid leukemia — Open Measurement Question | Across multi-center studies of adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, how can assay or instrument standardization for prognostic implications of myelodysplasia-related gene mutations eliminate inter-laboratory variabilit... | In adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine, how does prognostic implications of myelodysplasia-related gene mutations compare with legacy clinician-rated or unharmonized outcome assessment instrument regarding overall surv... | Can prognostic implications of myelodysplasia-related gene mutations safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 36 months compared with legacy clinician-rated or unharmonized outcom... | In oncology and hematology, managing acute myeloid leukemia in first complete remission (first complete remission (CR1)) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of prognostic implications of myelodyspla... | measurement | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Acute myeloid leukemia in first complete remission | Adults with intermediate- or adverse-risk acute myeloid leukemia in first morphologic remission after induction or venetoclax-azacitidine | PIRD | Prognostic implications of myelodysplasia-related gene mutations | Legacy clinician-rated or unharmonized outcome assessment instrument | 36 months | biomarker_discovery | multiple_small_studies | specialist_consensus_open | 1 | bounded | open | OPEN-VERIFIED | Chang YS et al., Lin J et al., Li R et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,026 | https://doi.org/10.3324/haematol.2025.288081 | Chang YS et al., Haematologica (2026); DOI: 10.3324/haematol.2025.288081 | NCT01347996 (PHASE4, COMPLETED): Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myel (SRC-MED-NCT-0011) | 3 | 5 | true |
UMED-000093 | 93 | Prophylactic Enoxaparin Dosing After Bariatric Surgery — Open Safety Question | What is the causal risk-benefit trade-off between gains in overall survival and progression-free or disease-free survival and cumulative Grade >=3 treatment-related and immune-mediated adverse events over 24 months when using guideline-directed clinical management and biomarker stratification in prophylactic enoxaparin... | In patients evaluated for prophylactic enoxaparin dosing after bariatric surgery in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in prophylactic enoxaparin dosing after bariatric surgery compare with alternative active comparator or standard dose-monitoring regim... | Among individuals with prophylactic enoxaparin dosing after bariatric surgery (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does guideline-directed clinical management and biomarker stratification in prophylactic enoxaparin dosing after bariatric surgery offer meaningful long-te... | In oncology and hematology, managing prophylactic enoxaparin dosing after bariatric surgery (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of prophylactic enoxaparin dos... | safety | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Prophylactic Enoxaparin Dosing After Bariatric Surgery | Patients evaluated for prophylactic enoxaparin dosing after bariatric surgery in oncology and hematology | PICOTS | Guideline-directed clinical management and biomarker stratification in prophylactic enoxaparin dosing after bariatric surgery | Alternative active comparator or standard dose-monitoring regimen | 24 months | post_authorization | one_pivotal_study | specialist_consensus_open | 2 | moderate | partially_resolved | PARTIAL-PROGRESS | Kennedy C et al., Kawahigashi T et al., Chen Y-H et al. & National Institutes of Health (NIH) Institute Strategic Research Plan | 2,026 | https://doi.org/10.1007/s11695-026-08825-9 | Kennedy C et al., Obesity surgery (2026); DOI: 10.1007/s11695-026-08825-9 | NCT07270263 (NA, RECRUITING): Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hema (SRC-MED-NCT-0025) | 3 | 5 | true |
UMED-000094 | 94 | Proximal vs. total gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy — Open Etiology Question | Using triangulated human causal inference in patients evaluated for proximal vs. total gastrectomy for proximal advanced gastric cancer after in oncology and hematology, is proximal vs. total gastrectomy for proximal advanced gastric cancer after neoadjuvant chemotherapy a modifiable causal driver of overall survival a... | In patients evaluated for proximal vs. total gastrectomy for proximal advanced gastric cancer after in oncology and hematology, how does proximal vs. total gastrectomy for proximal advanced gastric cancer after neoadjuvant compare with total gastrectomy regarding overall survival and progression-free or disease-free su... | What are the real-world benefits and risks of proximal vs. total gastrectomy for proximal advanced gastric cancer after neoadjuvant versus total gastrectomy over 60 months for patients managing proximal vs. total gastrectomy for proximal advanced gastric cancer after? | In oncology and hematology, managing proximal vs. total gastrectomy for proximal advanced gastric cancer after (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of proximal... | etiology | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Proximal vs. total gastrectomy for proximal advanced gastric cancer after | Patients evaluated for proximal vs. total gastrectomy for proximal advanced gastric cancer after in oncology and hematology | PECO | Proximal vs. total gastrectomy for proximal advanced gastric cancer after neoadjuvant | Total gastrectomy | 60 months | fundamental_human_mechanism | observational_only | active_scientific_dispute | 4 | very_hard | contested | DISPUTED-OPEN | Li Y et al., Chen GY et al., Szeglin B et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,026 | https://doi.org/10.3389/fonc.2026.1805000 | Li Y et al., Frontiers in oncology (2026); DOI: 10.3389/fonc.2026.1805000 | NCT07580339 (PHASE2, NOT_YET_RECRUITING): Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Adva (SRC-MED-NCT-0015) | 3 | 5 | true |
UMED-000095 | 95 | Radiotherapy Strategies for WHO Grade 1 Meningioma — Open Screening Question | In asymptomatic or at-risk patients evaluated for radiotherapy strategies for WHO Grade 1 meningioma in oncology and hematology, does structured screening via guideline-directed clinical management and biomarker stratification in radiotherapy strategies for WHO Grade 1 meningioma compared with symptom-prompted clinical... | In patients evaluated for radiotherapy strategies for WHO Grade 1 meningioma in oncology and hematology, how does guideline-directed clinical management and biomarker stratification in radiotherapy strategies for WHO Grade 1 meningioma compare with symptom-prompted clinical evaluation or current guideline screening sch... | For people with radiotherapy strategies for WHO Grade 1 meningioma, how does guideline-directed clinical management and biomarker stratification in radiotherapy strategies for WHO Grade 1 meningioma compare with symptom-prompted clinical evaluation or current guideline screening schedule for improving overall survival ... | In oncology and hematology, managing radiotherapy strategies for WHO Grade 1 meningioma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of radiotherapy strategies for WHO... | screening | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Radiotherapy Strategies for WHO Grade 1 Meningioma | Patients evaluated for radiotherapy strategies for WHO Grade 1 meningioma in oncology and hematology | PIRD | Guideline-directed clinical management and biomarker stratification in radiotherapy strategies for WHO Grade 1 meningioma | Symptom-prompted clinical evaluation or current guideline screening schedule | 24 months | population_health | observational_only | broad_consensus_open | 2 | moderate | open | BLOCKED-OPEN | Nitta H et al., Marinelli D et al., Queiroz S et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3390/cancers18152506 | Nitta H et al., Cancers (2026); DOI: 10.3390/cancers18152506 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000096 | 96 | Sentinel lymph node biopsy vs systematic lymphadenectomy for nodal staging in high-risk, early-stage endometrial cancer — Open Classification Question | Among patients with high-risk, early-stage endometrial cancer, can a reproducible subphenotype taxonomy based on sentinel lymph node biopsy vs systematic lymphadenectomy for nodal staging resolve clinical heterogeneity and improve overall survival and progression-free or disease-free survival stratification over 24 mon... | In patients with high-risk, early-stage endometrial cancer, how does sentinel lymph node biopsy compare with systematic lymphadenectomy regarding overall survival and progression-free or disease-free survival over 24 months? | In patients affected by high-risk, early-stage endometrial cancer, what is the clearest medical evidence on whether sentinel lymph node biopsy works better than systematic lymphadenectomy over 24 months? | In oncology and hematology, managing high-risk, early-stage endometrial cancer (early-stage disease) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of sentinel lymph node biopsy vs systematic lymphadenectomy f... | classification | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | High-risk, early-stage endometrial cancer | Patients with high-risk, early-stage endometrial cancer | prognostic | Sentinel lymph node biopsy | Systematic lymphadenectomy | 24 months | biomarker_discovery | multiple_small_studies | broad_consensus_open | 3 | hard | open | OPEN-VERIFIED | Queiroz S et al., Novara L et al., Li DY et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1016/j.ejogrb.2026.115462 | Queiroz S et al., European journal of obstetrics, gynecology, and reproductive biology (2026); DOI: 10.1016/j.ejogrb.2026.115462 | NCT06063070 (PHASE2, NOT_YET_RECRUITING): First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ov (SRC-MED-NCT-0035) | 3 | 5 | true |
UMED-000097 | 97 | Systemic Treatment Strategies Beyond Chemotherapy in Recurrent or Advanced Endometrial Cancer — Open Rehabilitation Question | For patients with recurrent or advanced endometrial cancer in ambulatory specialty rehabilitation pathways, does individualized therapy with systemic treatment strategies beyond chemotherapy produce durable gains in overall survival and progression-free or disease-free survival over 24 months versus usual physical and ... | In patients with recurrent or advanced endometrial cancer, how does systemic treatment strategies beyond chemotherapy compare with usual physical and functional care without structured rehabilitation pathway regarding overall survival and progression-free or disease-free survival over 24 months? | Can systemic treatment strategies beyond chemotherapy safely improve overall survival and progression-free or disease-free survival and quality of life (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 24 months compared with usual physical and functional care without structured rehabi... | In oncology and hematology, managing recurrent or advanced endometrial cancer (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of systemic treatment strategies beyond chem... | rehabilitation | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Recurrent or Advanced Endometrial Cancer | Patients with recurrent or advanced endometrial cancer | PICOTS | Systemic Treatment Strategies Beyond Chemotherapy | Usual physical and functional care without structured rehabilitation pathway | 24 months | comparative_effectiveness | multiple_small_studies | specialist_consensus_open | 4 | very_hard | open | OPEN-VERIFIED | Madár I et al., Higami S et al., Deng Z et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.3390/cancers18132091 | Madár I et al., Cancers (2026); DOI: 10.3390/cancers18132091 | NCT04240106 (PHASE2, COMPLETED): Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Br (SRC-MED-NCT-0036) | 3 | 5 | true |
UMED-000098 | 98 | Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers — Open Supportive Palliative Question | In managing complex symptom clusters in patients with advanced cancers, how does Time-of-Day immunotherapy administration and outcomes compare against usual symptom-directed care without integrated supportive pathway with respect to symptom control, Grade >=3 treatment-related and immune-mediated adverse events, and EO... | In patients with advanced cancers, how does Time-of-Day immunotherapy administration compare with usual symptom-directed care without integrated supportive pathway regarding overall survival and progression-free or disease-free survival over 24 months? | Among individuals with advanced cancers (including high-risk clinical subgroups, underrepresented age and comorbidity strata), does Time-of-Day immunotherapy administration offer meaningful long-term benefits over usual symptom-directed care without integrated supportive pathway across 24 months? | In oncology and hematology, managing advanced cancers (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of Time-of-Day immunotherapy administration and outcomes in advanced... | supportive_palliative | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Advanced Cancers | Patients with advanced cancers | PICOTS | Time-of-Day Immunotherapy Administration | Usual symptom-directed care without integrated supportive pathway | 24 months | comparative_effectiveness | systematic_review_low_certainty | specialist_consensus_open | 5 | frontier | partially_resolved | PARTIAL-PROGRESS | Inoue S et al., Bullard AJ et al., Wang Y et al. & World Health Organization (WHO) Global Research Agenda | 2,026 | https://doi.org/10.1001/jamanetworkopen.2026.10815 | Inoue S et al., JAMA network open (2026); DOI: 10.1001/jamanetworkopen.2026.10815 | NCT06827353 (OBSERVATIONAL, RECRUITING): Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Wit (SRC-MED-NCT-0034) | 3 | 5 | true |
UMED-000099 | 99 | Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma — Open Patient Experience Question | In patients with gastric and gastroesophageal junction adenocarcinoma, do patient-reported outcomes (EORTC QLQ-C30 health-related quality of life and symptomatic toxicity burden) over 36 months favor perioperative and neoadjuvant therapies or routine clinician-directed care without structured patient-reported decision ... | In patients with gastric and gastroesophageal junction adenocarcinoma, how does perioperative and neoadjuvant therapies compare with routine clinician-directed care without structured patient-reported decision tool regarding overall survival and progression-free or disease-free survival over 36 months? | What are the real-world benefits and risks of perioperative and neoadjuvant therapies versus routine clinician-directed care without structured patient-reported decision tool over 36 months for patients managing gastric and gastroesophageal junction adenocarcinoma? | In oncology and hematology, managing gastric and gastroesophageal junction adenocarcinoma (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of efficacy of perioperative and... | patient_experience | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Gastric and gastroesophageal junction adenocarcinoma | Patients with gastric and gastroesophageal junction adenocarcinoma | qualitative | Perioperative and neoadjuvant therapies | Routine clinician-directed care without structured patient-reported decision tool | 36 months | implementation | observational_only | active_scientific_dispute | 4 | very_hard | contested | DISPUTED-OPEN | Anjum MU et al., Medical Research Consortium et al., Zheng J et al. & Agency for Healthcare Research and Quality (AHRQ) Evidence-Based Practice Center | 2,025 | https://doi.org/10.1093/oncolo/oyaf157 | Anjum MU et al., The oncologist (2025); DOI: 10.1093/oncolo/oyaf157 | NCT03299946 (PHASE1, COMPLETED): Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Defi (SRC-MED-NCT-0045) | 3 | 5 | true |
UMED-000100 | 100 | Impacts of donor-specific anti-HLA antibodies on post-transplant clinical outcomes in hematopoietic stem cell transplantation — Open Health Services Question | In health systems managing patients with hematopoietic stem cell transplantation, how does organizing care delivery around impacts of donor-specific anti-HLA antibodies on post-transplant clinical outcomes compare with conventional specialty or hospital-centered care delivery model on overall survival and progression-f... | In patients with hematopoietic stem cell transplantation, how does impacts of donor-specific anti-HLA antibodies on post-transplant clinical outcomes compare with conventional specialty or hospital-centered care delivery model regarding overall survival and progression-free or disease-free survival over 36 months? | For people with hematopoietic stem cell transplantation, how does impacts of donor-specific anti-HLA antibodies on post-transplant clinical outcomes compare with conventional specialty or hospital-centered care delivery model for improving overall survival and progression-free or disease-free survival and minimizing Gr... | In oncology and hematology, managing hematopoietic stem cell transplantation (clinically characterized human cohort) requires balancing overall survival and progression-free or disease-free survival and Grade >=3 treatment-related and immune-mediated adverse events. Studies of impacts of donor-specific anti-HLA antibod... | health_services | oncology_and_hematology | 1 | Oncology and hematology | UMED-SET-01-GOLD | true | Hematopoietic stem cell transplantation | Patients with hematopoietic stem cell transplantation | health_systems | Impacts of donor-specific anti-HLA antibodies on post-transplant clinical outcomes | Conventional specialty or hospital-centered care delivery model | 36 months | health_system | observational_only | broad_consensus_open | 4 | very_hard | open | BLOCKED-OPEN | Liu M et al., Shafqat A et al., Zhang J et al. & U.S. Preventive Services Task Force (USPSTF) Evidence Gap Report | 2,025 | https://doi.org/10.1016/j.trim.2025.102275 | Liu M et al., Transplant immunology (2025); DOI: 10.1016/j.trim.2025.102275 | NCT07101588 (PHASE4, RECRUITING): Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (SRC-MED-NCT-0012) | 3 | 5 | true |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.